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Made up of brain micro-vessel endothelial cells, blood brain barrier (BBB) is a 
physiologic barrier between the blood and the central nervous system (CNS). It 
provides neurons with nutrition and isolates the CNS from toxic chemicals in the 
blood. However, it also severely restricts the delivery of therapeutic agents into the 
brain. Paclitaxel, one of the most widely used anti-cancer drugs, has limited 
application in treating brain tumor because of the existence of BBB. Of various 
strategies developed to enhance drug delivery to the brain, nanoparticles of 
biodegradable polymers show great potential because they can conquer BBB 
non-invasively and achieve prolonged pharmacological action of drug molecules. 
In this research, paclitaxel loaded poly (D,L-lactide-co- glicolide) (PLGA) 
nanoparticles were fabricated using single emulsion technique. The emphasis was put 
on the effect of surfactants of nanoparticles. Chemical surfactant polyvinyl alcohol 
(PVA) and natural surfactants DPPC, vitamin E TPGS were used. Nanoparticles of 
sizes around 250nm with narrow size distribution and negative surface charge were 
achieved. Scanning electron microscopy (SEM) and atomic force microscopy (AFM) 
images showed the morphologies of these nanoparticles. It was found that vitamin E 
TPGS emulsified nanoparticles had much higher encapsulation efficiency than the 
other two batches. All batches of nanoparticles had sustained in vitro release in about 
a month. Cell viability study was carried out using rat glioma cell line C6 to test 
paclitaxel loaded nanoparticles’ potential to treat brain tumor. It was found that time 
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and concentration had effect on the viability.  
Cell uptake and confocal laser scanning microscopic studies revealed that fluorescent 
marker coumarin-6 loaded PLGA nanoparticles were ready to cross the in vitro BBB 
model- Madin-Darby Canine Kidney (MDCK) cell line, but the uptake percentage 
was affected by surfactants. Particle size effect on cellular uptake was also studied 
using fluorescent polystyrene nanoparticles with uniform particle sizes. In vivo 
experiment was carried out subsequently. PLGA nanoparticles were overcoated with 
tween 80 before injecting to the tail vein of the rats. Fluorescence was detected both 
in rat brain vessels and tissues under fluorescence microscope. 
MRI contrast agent Gadolinium-DTPA loaded biodegradable nanoparticles were also 
developed for future non-invasive in vivo imaging. Besides size, morphology, drug 
entrapment and in vitro release study, MRI characteristics of Gd-DTPA encapsulated 
nanoparticles were also investigated.  
Overall, this research conducted systematic investigation on feasibility of 
nanoparticles of biodegradable polymers for drug delivery across the blood brain 
barrier. It was found that emulsifiers and particle size played an important part on 
nanoparticles’ ability to cross BBB. Preliminary research on MRI contrast agent 
Gd-DTPA encapsulated nanoparticles for future non-invasive in vivo imaging was 
also investigated. These results will provide comprehensive information on 
nanoparticles of biodegradable polymers as potential drug carriers to treat brain 
cancer and brain related diseases such as AIDS.     
 vii
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Brain cancer is caused by uncontrolled cell growth in the brain. It can be divided into two 
categories: the primary brain cancer which is originated within the brain and the 
secondary brain cancer which is originated from cells in other parts of the body and 
migrate to the brain (oncology channel). Although a lot of efforts have been exerted, 
brain cancer still remains one of the most difficult diseases to treat mainly because the 
existence of the blood brain barrier. The blood brain barrier (BBB) is a physiological 
mechanism that alters the permeability of the brain capillaries so that some substances 
such as the toxins and drugs are prevented from entering the brain while necessary 
nutrition is allowed to enter freely. Although BBB plays an important role in maintaining 
a homeostatic environment for the brain, it also represents a main obstacle for 
chemotherapy of brain diseases. Paclitaxel, a widely used anticancer drug, has limited 
application in treating brain tumors because of its poor solubility and BBB permeability. 
Due to its low solubility, paclitaxel is often administered together with Cremophor EL as 
a co-solvent which can cause a lot of side effects (Weiss, 1990; Kongshaug, 1991; Dorr, 
1994; Fjallskog, 1993).  P-glycoprotein, which is abundantly distributed in the BBB, 
serves as a biochemical barrier and is responsible for paclitaxel’s poor brain permeability. 
Various carriers have been developed to formulate paclitaxel without the toxic co-solvent 
(Singla et al., 2002), among which nanoparticles of biodegradable polymers seem to be 
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an ideal option. However, little information can be found from literature about efficient 
brain delivery of paclitaxel loaded nanoparticles. On the contrary, nanoparticle 
formulation for enhanced brain drug delivery often uses water soluble drugs such as 
darlagin, doxorubicin as model drug due to their poor bioavailability (Schroeder et al., 
1998; Gulyaev et al., 1999). 
In previous studies, poly(butylcyanoacrylate) (PBCA) was often used as working 
polymer for enhanced drug delivery to cross the blood brain barrier. However, PBCA is 
not authorized and may have toxicity effects on CNS (Oliver, et al, 1999; Davis, 2000). 
Therefore, it is of significance to choose a polymer with more favorable properties to 
develop nanoparticles. Poly (D,L-lactide-co-glycolide) (PLGA), a widely used 
biodegradable polymer which has been approved by Food and Drug Administration 
(FDA), is a good candidate. Due to its unique advantages over other polymers such as 
biodegradability, biocompatibility and ability for sustained release, PLGA has been 
broadly applied in drug delivery. 
Apart from the nature of polymers, proper surfactant and particle size are two important 
factors that can affect nanoparticles’ fate both in vitro and in vivo. It was found that 
nanoparticles overcoated with some chemical surfactants such as poloxamer 407, 
poloxamer 188 and polysorbate 80 could yield much higher uptake by bovine brain 
microvessel endothelial cells (Borchard et al, 1994). Researchers also found that particle 
size could significantly affect cellular and tissue uptake. The uptake efficiency of 
nanoparticles was much higher than that of microparticles (Panyam and Labhasetwar, 
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2003). However, very limited studies have been carried out for the application of natural 
surfactant and particle size effect on brain delivery. 
When in vivo experiments are carried out to evaluate drug delivery to the brain, indirect 
or invasive methods such as the hot-plate test, tail-flick test and fluorescent brain slice are 
often adopted (Kreuter et al., 1995; Ramge et al., 1999; Sun et al., 2003). These methods 
help us to know the efficiency of drug carriers in vivo qualitatively.  However, the 
specific delivery site can not be assessed readily. As a high contrast imaging instrument, 
magnetic resonance imaging (MRI) is very useful in medical field. Contrast agent such as 
iron oxide and gadolinium-DTPA can be used to enhance the imaging significantly. By 
encapsulating MRI contrast agent into the nanoparticles, it is possible to visualize the 
exact site of nanoparticles in vivo with a noninvasive way. Up to now, only two very 
recent papers presented similar ideas of using Gd-DTPA encapsulated microparticles for 
bladder imaging (Faranesh et al., 2004; Chen et al., 2005). No literature has been found 
about using positive contrast agent Gd-DTPA loaded nanoparticles for brain imaging.      
1.2 Objectives 
A series of experiments will be carried out to investigate the feasibility of PLGA 
nanoparticles to cross the BBB both in vitro and in vivo. The research will be focused on 
surfactant coating technique and particle size effect.  The potential for treating brain 
cancers with therapeutic agent paclitaxel loaded PLGA nanoparticles will also be 
investigated by cell line experiment. Besides, MRI contrast agent Gd-DTPA loaded 
nanoparticles of biodegradable polymers are also developed for future investigation of 
non-invasive imaging of nanoparticles in vivo. 
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In the therapeutic agent/fluorescence loaded nanoparticles study, paclitaxel or fluorescent 
marker coumarin-6 loaded PLGA nanoparticles will be fabricated using the 
extraction/evaporation method. Two natural surfactants: vitamin E TPGS and DPPC (1,2- 
dipalmitoyl-sn-glycerol-3-phospatidylchlorine) will be tried as novel emulsifiers and 
surface coating during the fabrication process compared with traditional emulsifier PVA 
(polyvinyl alcohol). Particle size and size distribution will be measured with the laser 
light scattering (LLS) system. Surface charge will be determined by the zeta potential 
analyzer. Scanning electron microscopy (SEM) and atomic force microscopy (AFM) 
allow us to get a close look at the particle morphology. Encapsulation efficiency and in 
vitro release of paclitaxel from the nanoapheres are measured by the high performance 
liquid chromatography (HPLC). MDCK (Madin-Darby canine kidney) cell line will be 
used as a simple in vitro BBB model for uptake study of fluorescence loaded PLGA 
nanoparticles. Direct evidence of cellular uptake of nanoparticles will be presented by 
confocal study. Particle size effect will also be detected by MDCK cell uptake 
experiment using commercially available fluorescent polystyrene nanoparticles with 
uniform particle sizes. The potential for drug loaded PLGA nanoparticles to treat brain 
tumors will be verified by cell viability study using MTT assay with rat brain tumor cell 
line C6 as the model. Finally, preliminary in vivo study will also be carried out by 
observing brain tissue slice under fluorescence microscopy after injection of fluorescence 
loaded PLGA nanoparticles to the rats. 
In the MRI contrast agent loaded nanoparticles study, Gd-DTPA loaded nanoparticles of 
biodegradable polymers such as PLGA and MPEG-PLA will be developed with different 
fabrication methods. The achieved nanoparticles with favorable properties will be 
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characterized by LLS, zeta potential analyzer and SEM. Inductively coupled plasma - 
optical emission spectrometer (ICP-OES) will be used to measure drug entrapment and in 
vitro release profiles. MRI characteristics of the contrast agent loaded nanoparticles will 
also be investigated.  
1.3 Thesis Organization 
The body of this thesis is made up of seven chapters. Chapter 1 gives a brief introduction 
to the project. It comprises of the general background as well as the objectives of the 
proposed project. Chapter 2 is literature review on brain cancer, blood brain barrier, 
paclitaxel and various technologies to fabricate nanoparticles. Known research on 
nanoparticles to enhance CNS drug delivery will also be described in this chapter. In 
chapter 3, the materials and methods used in all experiments are recorded. The 
experimental results and discussions are presented in chapter 4 and chapter 5. In chapter 
4 and 5, we present the results of applying paclitaxel and fluorescence marker loaded 
nanoparticles of biodegradable polymers respectively for treating brain cancer cells and 
enhancing brain drug delivery. In chapter 6, we develop novel MRI contrast agent loaded 
nanoparticles for imaging purpose. Conclusion drawn from the project and 







2.1 Paclitaxel and Its Limitations in Modern Chemotherapy 
Discovered in 1971(Wani et al., 1971) and first approved by US FDA in 1992 for 
treatment of ovarian cancer, paclitaxel becomes one of the most promising anti-cancer 
drugs that can deal with a wide spectrum of cancers such as ovarian, breast and non-small 
cell lung cancers. It also has application in treating brain related diseases like AIDS (Feng 
& Shu, 2003; Lopes et al., 1993; Donehower et al., 1987; Panchagnula, 1998). Paclitaxel 
exerts its effect by blocking the replication of cancer cells in the late G2-mitotic phase. 
The interaction between paclitaxel and cells makes microtubules dysfunctional and leads 
to apoptosis of cancer cells (Horwitz, 1992). 
Despite the effectiveness of paclitaxel in chemotherapy, it also has quite a few limitations. 
These are also limitations in current chemotherapy.  The reasons mainly lie in the 
following four aspects:  
(1) Availability. Paclitaxel was extracted from the bark of very slow-growing west 
yew with low extraction rate (<0.04%) (Cragg, 1991). In order to solve the 
problem, alternative sources for preparation of semi-synthetic taxol and taxol 
analogues have been found, such as needles and twigs of English yew trees or 
Chinese red bean yew trees. Unlike the bark, the needles can regenerate and 
provide a continuous source for production (Horwitz, 1992). However, efficient 
 6
and low-cost ways of large-scale synthesis of paclitaxel still remains a challenge. 
(2) Dosage form and toxicity. In 1971, Wall and his colleagues first reported the 
structure of taxol and its cytotoxicity to KB cell line and mouse leukemia cells 
(Wani, 1971). It is obvious that paclitaxel has some benzene rings and other 
hydrophobic structures (refer to Fig 2.1 below), which lead to its low water 
solubility of less than 0.5mg/L. There is no way for direct injection of paclitaxel 
by dissolving it in distilled water, the only dosage form available in clinical 
administration uses Cremophor EL and dehydrated alcohol as adjuvant, which is 
rather toxic and can cause serious side effects such as hypersensitivity reaction, 
neurotoxicity, cardiotoxicity and nephrotoxicity (Weiss, 1990; Kongshaug, 1991; 
Dorr, 1994; Fjallskog, 1993 ). 
                         
                                 Fig 2.1 Chemical structure of paclitaxel    
(3) Drug Resistance and bioavailability. It has been found that paclitaxel is able to 
induce the multidrug resistance (MDR) phenotype with overexpression of P-
glycoprotein (P-gp) (Horwitz, 1992; Roy & Horwitz, 1985; Greenberger et al., 
1987; Drion et al., 1996). P-gp exists in the cell membrane and serves as a kind of 
efflux pump that can prevent drugs and other toxic substances from entering cells 
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(Gatmaitan & Arias, 1993). P-gp is widely distributed in many tissues, such as 
gastro-intestinal tract, kidney and blood brain barrier. It has already been found 
that paclitaxel has a rather high affinity for P-gp transporter. Another problem is 
when drugs are administered, especially orally, they have to withstand metabolic 
barriers before reaching the blood system. There are a lot of digestive enzymes 
throughout the GI tract which can degrade drugs and further result in a low 
bioavailability.  
(4) Targeted and controlled release. Although paclitaxel has excellent effect on tumor 
cells, it can also harm normal cells, especially cells that divide quickly such as the 
bone marrow and lining of the GI tract. Many dangerous side effects may be 
caused by this kind of non-specific action, such as loss of hair, fussy thinking and 
difficult concentrating. Another problem is that in order to achieve therapeutic 
effect, drug concentration should be between the therapeutic level, i.e., above the 
minimum effective level but below the toxic level. Thus the initial burst should be 
lowered to achieve a prolonged and sustained release. Besides, drugs may be cell-
cycle or cell-growth-phase specific. Thus, cell-cycle specific drugs can be 
developed to achieve maximum effect (Ratain et al., 1990). Briefly, the desired 
pharmacokinetics is to release a sufficient quantity of drugs at the right time, the 
correct location and over a long period of time. 
2.2 Brain Cancers and Blood Brain Barrier (BBB) 
2.2.1 Brain Cancers and Cancer Treatment 
Cancer is a group of diseases characterized by uncontrolled cell division leading to 
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growth of abnormal tissues. Cancer can spread from its original site to other parts of the 
body and can be fatal (Web definitions for cancer). Every year, more than 10 million 
people are diagnosed with cancer and 6 million people die of cancer, which accounts for 
12% of deaths worldwide. Although brain cancers are rare cancers which represent only 
1.5% of all cancers, the death rate of brain cancers is very high. Moreover, brain cancer 
also ranks second in all childhood cancers, representing 21% of childhood cancer cases 
(American Cancer Society). There are basically two kinds of brain tumors. One is 
primary brain tumors which start in the brain, the other is metastatic brain tumors which 
are cancers from other parts of the body that can spread to the brain and cause secondary 
tumor through a process called metastasis. The cells of a metastatic brain tumor resemble 
the cells of the organ where the tumor startes, not brain cells. 
Like other cancers, effective treatments of brain cancers include surgery, radiotherapy, 
chemotherapy, hormone therapy, biotherapy, and immunotherapy (Oncology, 2002). Two 
or more methods are often used in combination to achieve better effects. Surgery is the 
primary method for treatment of brain tumors that can be removed without damaging 
critical neurological functions. Radiation therapy and chemotherapy are often combined 
with surgery as secondary and adjuvant treatment. However, severe side effects often 
accompany these treatments. One of the most important factors that limit brain cancer 
chemotherapy is due to the existence of the blood brain barrier. 
2.2.2 Introduction to the Blood Brain Barrier 
2.2.2.1 History of Blood Brain Barrier 
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The concept of blood brain barrier was first raised by the German scientist Paul Ehrlich 
in 1885(Enrlich, 1885). After that, many studies have been carried out on this important 
physiologic barrier. Table 2.1 gives a brief summary of the research history on BBB.  
Table 2.1 Summary of BBB History 
Discoverer             Time                                       Main Point 
Ehrlich P                1885            i.v. injection of acidic vital dyes stain all rabbits body      
                                                  except brain and spinal cord (Enrlich, 1885)                                                  
Lewandowsky        1900          coin the term blood-brain barrier while studying potassium                              
                                                  ferrocyannide penetration into the brain (BBB history) 
 Goldmann EE        1909           i.v. injection of trypan blue to cerebrospinal fluid stains  
                                                  entire brain but not the internal organs(Goldmann, 1909) 
Gautier& Stern       1920s          bile salt, morphine and bromide appear in CSF while bile 
                                                   pigment, epinephrine and curare not after i.v. injection 
Broman                   1941           tight junction not the astrocytic end forms barrier function 
                                                   of BBB (BBB history) 
Reese& Karnovsky 1967          visulize BBB using electron microscope & traceable  
Reese et al.              1970          proteins, revealing the protein diffuse past astrocytic 
                                                  end feet and stop at tight junction (Reese & karnovsky, 
                                                  1967; Reese et al., 1970) 
Weiler-Guttler        1989           characteristics of BBB; studies in molecular biology of  
                                                  BBB, cloning and sequencing glucose transporter gene 
                                                  (weiler-Guttler et al., 1989) 
Muldoon LL           1999           BBB is a physiologic barrier (Muldoon et al., 1999) 
 
2.2.2.2 Structure and Function of the Blood Brain Barrier 
The blood brain barrier is created by tight apposition of endothelial cells lining blood 
vessels in the brain and is surrounded by astrocyte foot process. A thin basement 
membrane surrounds the endothelial cells and associated pericytes, providing mechanical 
support as well as a barrier function. The part in the circle in Fig 2.2 is the BBB site. 
There are quite a few important differences between the ultrastructure of brain blood 
vessels and systemic blood vessels. The brain capillaries lack fenestration that exists in 
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other systemic capillaries, instead, the membrane of the endothelial cells in the brain is 
fused into tight junctions, forming continuous, uninterrupted structures. These endothelial 
tight junctions are the anatomical site of BBB and play an important role in preventing 
the free exchange of substances between blood and brain (Brightman & Reese, 1969; 
Reese et al., 1970).The tight junctions result in a much higher transendothelial electrical 
resistance than other tissues (>50 times), which makes the BBB more hydrophobic and 
reduces the aqueous based paracellular transport (Lo et al., 2001). BBB also possesses 
specific enzyme systems, glucose transporters and protein receptors, which indicates its 
special mechanisms in exchanging substances.  Moreover, blood brain barrier is 
incorporated with many efflux proteins such as P-glycoprotein (P-gp), multidrug 
resistance protein (MRP). These proteins are responsible for ATP-dependent outward 
transport of a wide range of substances, including many therapeutic agents (Crone, 1971).  
The major function of the blood brain barrier is to protect the brain from possible toxins 
while supply it with necessary nutrients. Thus it acts both as an impermeable wall and a 
selective sieve (Betz, 1992). Due to its special structures mentioned above, blood brain 
barrier effectively filters most ionized, water-soluble molecules greater than 180 Daltons 
and substances that are substrates of its efflux system. Only small, lipophilic molecules 
can cross the BBB (Lee,2001;Kroll& Neuwelt, 1998). Several mechanisms are known to 
be involved in the transport of substances across BBB. Only a few substances such as 
water can enter the brain using the paracellular route because of the existence of the tight 
junction. Lipophilic molecules can cross BBB by simple diffusion through transcellular 
pathway. Lipophilicity and hydrogen bonding potential determine the ability of molecules 
to cross BBB (Egleton& Davis, 1997). However, a large family of lipid soluble 
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substances is also substrates of efflux P-gp system thus results in poor brain uptake 
(Tamai& Tsuji, 2000). BBB’s selectivity also indicates that a specific carrier system 
exists to transport small polar solutes such as glucose (Begley, 1996). Carrier mediated 
transport in BBB is a major system for endogenous substances and nutrients to enter the 
brain. Finally, endocytic mechanisms, whether specific or adsorptive, are responsible for 
the transport of large proteins and peptides across BBB. 
2.2.2.3 In Vitro and In Vivo Models of Blood Brain Barrier 
(a) In Vitro BBB Models 
In vitro BBB models can only represent part of the properties of in vivo BBB and they 
share some basic characteristics. Currently, three types of brain capillary endothelial cell 
culture are essentially in use: primary cultures, cell line and co-culture systems.  
Isolated brain capillaries represent the first developed and closest to in vivo system of in 
vitro BBB models (Joo, 1992; Pardridge, 1998). The system next closest is primary brain 
endothelial cells (BEC) isolated from or grow out of brain capillary fragment. However, 
due to the difficulty to prepare primary BEC, a number of immortalized cells have been 
developed to act as in vitro BBB model.  At present, there are more than 15 different cell 
line models, including immortalized bovine BEC lines, porcine BEC lines, murine cell 
lines, primary rat BECs and human cell lines (Durieu et al., 1991; Teifel and Friedl, 1996; 
Wijsman and Shievers ,1998; Mooradian and Diglio, 1991; Muruganandam et al.,1997). 
The last in vitro BBB model is the co-culture system which consists of a co-culture of 
brain capillary endothelial cells on one side of a filter and astrocytes on the other. The 
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strong correlation between this model and in vivo situation demonstrates it an important 
tool for studying the drug delivery to the blood brain barrier (Dehauck et.al., 2000). 
 
(b) In Vivo Techniques 
The most common techniques for in vivo study of blood brain barrier include the 
intravenous injection method, the brain efflux index (BEI), the brain perfusion and the 
micro-dialysis. Table 2.2 below gives a brief summary of these methods. 
Table 2.2 Summary of in vivo techniques to study BBB 
   Methods                                                                Description  
  i.v. injection                  “gold standard” for all BBB work; inject solute intravenously,  
                                         determine solute concentration in brain, plasma and CSF at 
                                         different times; system intact, reflect true in vivo situation;  
                                         complexity often affects data.  
                                         Representative work: Ehlich, 1885 
 
brain efflux index            defined as “amount of drug effluxed at BBB” over “amount of 
                                         drug injected into the brain”; involve direct microinjection of 
                                         test solute and reference tracers into the brain; can be used to 
                                         investigate mechanisms of brain-to-blood efflux. 
                                         Representative work: Kakee et al., 1996 
 
in situ brain perfusion      replace circulation to brain via direct infusion of saline with  
                                         solute of known concentration to the brain or major vessels for 
                                         a known interval, perfusion is stopped at set time and amount 
                                         of solute in brain is determined; relative simple to study kinetics 
                                         of brain uptake, transport or permeability constants. 
                                         Representative work: Takasato et al., 1984; Smith, 1996  
 
micro-dialysis                   physiological perfusate is pumped through the semi-permeable   
                                          microdialysis probes in CNS, compounds in extracellular fluid 
                                          diffuse into perfusate and their concentration can be measured 
                                          by HPLC, thus tissue concentration of solutes can be measured; 
                                          quantitatively determine transport across BBB and brain influx 
                                          and efflux kinetics; invasive, can cause dysfunction of BBB. 




2.2.2.4 Strategies to Conquer the Blood Brain Barrier 
While the characteristics of blood brain barrier provide a formidable obstacle for drug 
delivery to CNS, it is not insurmountable. A variety of strategies have been developed to 
enhance drug delivery to the brain (Misra et.al., 2003). They can mainly be divided in 
two categories: BBB manipulation and drug manipulation.  
(a) BBB Manipulation 
Methods that belong to the BBB manipulation include: osmotic disruption of BBB, 
biochemical methods to open BBB and alternative routes to overcome BBB. 
Rapoport et al. demonstrated that intracarotid injection of inert hypertonic solutions such 
as arabinose would artificially create osmotic pressure and resulted in more than 20 folds 
increase in brain concentration of hydrophilic drugs (Rapoport et.al., 1978). In contrast to 
osmotic disruption of BBB, biochemical methods can selectively open brain tumor 
capillaries and are potentially safer. Sanovich et al. discovered increased permeability of 
BBB to lanthanum due to the administration of the bradykinin analog RMP-7 (Sanovich 
et al., 1995). However, disruption of BBB will cause unexpected damage to the brain 
such as entering of toxins, abnormal neuronal functions and altered glucose uptake 
(Miller, 2002). The last method is to develop methodologies not relying on the 
cardiovascular system, thus bypass BBB altogether. Alternative routes include 
intraventricular, intrathecal, olfactory route and direct brain interstitial delivery (Misra et 
al., 2003). Slow rate of drug distribution, clinical incidence of hemorrhage and CNS 
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infection, active nasal enzyme activity need to be overcome in further investigation of 
this method. 
(b) Drug Manipulation 
Drug manipulation includes prodrug, lipophilic analogs, chemical drug delivery, carrier 
mediated drug delivery and receptor/vector mediated drug delivery. Prodrug is 
pharmacologically inactive compounds by modification of the parent drug. After 
administration, prodrug comes to site of action more readily and maintains for a longer 
time due to its own characteristics; the drug will then convert to its active form to take 
effect by a single activating step. Lipophilic analogs allow drugs to become more lipid 
soluble, thus can increase its ability to cross the BBB. One example of this is the 
liposome. PEGylated immuno-liposomes can cross the BBB in vivo through receptor 
mediated transport (Huwyler et. al., 1997). Chemical drug delivery is to target active 
biologic molecules to certain sites based on predictable enzyme activation. Carrier, 
receptor and vector mediated drug delivery to the brain brings in the chimeric peptide 
technology, where non-transportable drugs such as peptide are conjugated to a BBB 
transport vectors. Nanoparticles have become one of the most popular and promising 
vectors for drug transportation across the blood brain barrier (Kreuter et. al., 1995; 
Peppas and Blanchette, 2004).  
2.3 Nanoparticles of Biodegradable Polymers for Drug Delivery 
Nanoparticles are colloidal particles of sizes ranging from 1nm to 1000nm. Drugs are 
dissolved, entrapped or encapsulated in the particles (Lockman et al., 2002). The use of 
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nanoparticles for drug delivery offers several advantages which include improved 
bioavailability through sustained release, protection of drugs from degradation and 
premature inactivation, reduced toxicity to normal cells through targeted delivery by 
surface modifications of the nanoparticles and increased ability to conquer the P-
glycoprotein through masking the drug from being recognized by P-gp. There has been 
wide research on nanoparticles of biodegradable polymers for drug delivery. 
2.3.1 Basic Information of Biodegradable Polymers  
Biodegradable polymers are widely used for drug delivery and controlled release because 
they eliminate the need of removing delivery systems after administration. Drugs are 
released from polymer matrix by diffusion, polymer degradation or erosion. Various 
kinds of biodegradable polymers have been developed and summarized in table 2.3 
(Uhrich et.al., 1999). 
Table 2.3 Summary of biodegradable polymers for drug delivery 
   Type                                              Description& Representative Polymers  
 Biopolymers             natural polymers, especially poly(saccharide) family, such as starch, 
                                   cellulose, chitosan. 
 
 Poly(esters)               best studied biodegradable system with product in clinical use; can 
                                   be synthesized using ring-opening polymerization; representative 
                                   polymers include poly(lactic acid), poly (glycolic acid) and their  
                                   copolymers, poly (ethylene glycol) block copolymers. 
 
 Poly(ortho esters)      allow release of drugs after polymer chain hydrolysis, research on 
                                   this polymer focuses on  adding polyols to diketene acetals such as 
                                   3,9-diethylidene-2,4,8,10-tetraoxaspiro[5.5] undecane(DETOSU) 
 
 Poly(anhydrides)      allow heterogeneous erosion and mainly undergo surface erosion; 
                                   prepared by melt-condensation polymerization; representative poly- 
                                   mers are based on p-(carboxyphenoxy) propane (CPP), sebacic 
                                   acid (SA) and p-(carboxyphenoxy) hexane (CPH). 
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 Poly(amides)             amino acid-derived polymers, mainly deliver low molecular weight 
                                   drugs; degradation rate depends on hydrophilicity of amino acid; 
                                   representative polymers include poly(lactic acid-co-lysine) (PLAL). 
 
 Phosphorus-              can perform substitution reactions; have unique inorganic P-N 
Containing Polymer   backbones; representative polymers include poly(phosphazenes) 
                                   and poly(phosphoesters). 
 
Among all the biodegradable polymers used for drug delivery, poly(lactic acid-co-
glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) block copolymers receive wide 
attention and investigation. Both of them are FDA approved polymers and have been 
used in clinical trials (Beck et. al., 1983). They are especially broadly used in fabricating 
micro and nano spheres as drug carriers for controlled release. Fig 2.2 below shows the 
chemical structures of PLA, PLGA, PEG and PEG included diblock copolymer MPEG-
PLA. 
                   (a)            (b)    
                (c)             (d) 
Fig 2.2 Chemical structures of PEG(a), MPEG-PLA(b), PLA(c) and PLGA(d)  
PLGA is the copolymers of lactic and glycolic acid (PLA and PGA). It has faster 
degradation rate than that of PLA and its degradation products are natural metabolites 
(Leong and Langer, 1987). The degradation rate of PLGA varies within months with 
different L:G ratios. Release from PLGA microcapsules and microspheres has been 
emphasized since steroids have low permeability in PLGA (Beck et.al., 1983). It is 
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suggested that the release kinetics of the microparticles are initial diffusion plus a later 
combined erosion and diffusion ( Leong and Langer, 1987). 
PEG and its high molecular weight form PEO (poly(ethylene oxide)) have very good 
biocompatibility. Due to its hydrophilic nature, PEG also has good protein resistivity 
(Kwon and Kataoka, 1995; Torchilin and Papisov, 1994). Proteins will have longer 
circulation time and avoid being taken up by the RES system in the body by attaching 
PEG chains to the surface of them. Many groups also have a deep investigation on PEG 
block copolymers. Methoxy poly(ethylene glycol)-poly(lactide acid) (MPEG-PLA)  is the 
diblock copolymer of PLA and methoxy PEG. MPEG-PLA possesses amphiphilic 
structures thus have surfactant properties. The inclusion of PEG into copolymers will 
help them to have more favorable properties to be used as drug carriers. For example, 
MPEG-PLA nanoparticles have more blood circulation time than that of PLA 
nanoparticles in vivo (Gref et al., 1994). Other PEG block copolymers such as triblock 
PLA-PEG-PLA and multi-block copolymer of L-lactide and ethylene oxide have also 
been developed (Uhrich et al.,1999). 
2.3.2 Manufacture Techniques of Nanoparticles  
Various methods have been developed to fabricate nanoparticles. Basically, they are 
either by dispersing preformed polymers or by polymerizing monomers (Feng and Chien, 
2003). Some common methods for fabricating nanoparticles are summarized below. 
(1) Solvent evaporation/extraction process. This method includes single emulsion and 
double (multiple) emulsion. Single emulsion, which is also referred to as oil-in-water 
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(o/w) method, is often used to encapsulate hydrophobic drugs. Briefly, the preformed 
polymer and drug are dissolved or dispersed in a water immiscible organic solvent such 
as dichloromethane (DCM) and chloroform. After sonication, the organic phase is slowly 
poured into water phase containing amphiphilic emulsifiers. The mixture then undergoes 
high-speed homogenization. Then the organic phase is evaporated or extracted before 
centrifuging to remove the excess emulsifiers. The final product is obtained by drying the 
emulsion under suitable conditions. For encapsulating hydrophilic drugs such as proteins 
and peptides, double emulsion (water-in-oil-in-water) is often used. This method is most 
similar to that of single emulsion except that the aqueous solution of the drug is added to 
the polymer contained organic solvent with sonication to form the first w/o emulsion 
before putting that into the water phase (Jain, 2000). 
(2) Spontaneous emulsification/solvent diffusion process. This method is sometimes 
referred to as the nanoprecipitation method. Polymer and drug (either hydrophobic or 
hydrophilic) are dissolved or dispersed in a mixture of water soluble organic solvent such 
as acetone and water-insoluble solvent such as DCM. Then the organic phase is added to 
the aqueous phase drop by drop. Nanoparticles are formed at the same time. The 
spontaneous diffusion of water-soluble solvent creates an interfacial turbulence between 
oil and water phase leading to the formation of smaller particles (Dong and Feng, 2004).  
(3) Spray Drying. Spray drying is a fast and convenient method suitable for mass 
production. It is appropriate for both hydrophilic and hydrophobic drugs and less 
dependent on polymer species (Wagenaar and Muller, 1994). Briefly, drugs are suspended 
or dissolved in organic solution where polymer is also dissolved. Then the mixture is 
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spray dried to produce particles. 
(4) Phase separation method (coacervation). This method is applicable to both 
hydrophilic and hydrophobic drugs. Briefly, polymer is dissolved in an organic solvent 
before the drug is dissolved or dispersed in it. Then an organic nonsolvent is added to the 
above system with stirring to extract the polymer solvent. Due to the phase separation, 
the polymer forms soft coacervate droplets entrapping the drug. Then the system is 
transferred to another organic nonsolvent of large amount to harden the particles and 
form final product (Jain, 2000).  
(5) Polymerization of monomers. Polymerization includes emulsion polymerization and 
interfacial polymerization. Emulsion polymerization builds up a chain of polymers from 
single monomers. The process initiates by radical or ion formation and residual monomer 
is removed by filtration. The finally formed nanoparticles can act as drug carriers by drug 
adsorption. Interfacial polymerization happens when monomer-contained organic phase 
and aqueous phase are brought together by mechanical force. This process can 
encapsulate drugs by adding them with monomer in the organic phase (Couvreur et al., 
1979; Lockman et al, 2002). 
Other methods include salting out, superficial fluid spraying, solid lipid nanoparticles etc. 
Polymer type, co-polymer ratio, drug loading level, mechanical strength level, emulsifiers 
added, temperature, pH, molecular weight etc. exert effect together to determine the 
characteristics of nanoparticles (Feng and Chien, 2003). 
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2.3.3 Current Research on Biodegradable Nanoparticles across BBB 
Of so many strategies discussed previously to conquer the blood brain barrier and treat 
brain tumors, nanoparticles seem to be a strong candidate due to their biocompatibility, 
possibility for sustained release and ability to mask the P-gp efflux system. Lockman et al. 
summarized the ideal properties of polymeric nanoparticles across the BBB, which 
includes: nontoxic, biodegradable/biocompatible of the polymers; nonthrombogenic and 
nonimmunogenic to human body; small particle size (<100nm); BBB targeting; stable in 
blood; prolonged circulation time; ability to escape reticuloendothelial system (RES) etc. 
(Lockman et al., 2002). 
 Up to now, many researches have been carried out on polymeric and lipid nanoparticles 
to cross the blood brain barrier. Table 2.4 below gives a summary of various drugs loaded 
nanoparticles being delivered to the brain. Among them, polysorbate 80 or tween 80 
coated polybutylcyanoacrylate (PBCA) nanoparticles are the most well studied system 
which has successfully delivered a number of therapeutic agents such as hexapeptide 
dalargin, doxorubicin, loperamide and amitriptyline to the brain of rats or mice. 
Polysorbate coated nanoparticles not only deliver these drugs that normally can’t cross 
BBB but also increase the plasma half-life of these drugs due to their favorable surface 
characteristics. Moreover, CNS availability of these drugs also increases through 
sustained release (Kreuter, 2001; Alyautdin et al., 1997, Schroder and Sabel, 1996; 
Gulyaev et al., 1999, Chen et al., 2004). Despite the success of tween 80 coated PBCA 
nanoparticles being transported to the brain, there is always dispute on whether the 
polysorbate coated PBCA nanoparticles have toxic effect on BBB. Oliver et al. suggested 
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that the breakdown of PBCA nanoparticles by ubiquitous esterases would cause toxic 
effect on BBB based on a co-culture system. They also observed a mortality of mice (3 to 
4 out of 10 mice) caused by PBCA nanoparticles. Thus they proposed the possibility of 
nonspecifically opening of tight junctions between endothelial cells in brain 
microvasculature by PBCA nanoparticles. However, Gelperina et al. reported no 
mortality or weight loss of  rats after injection of doxorubicin loaded PBCA nanoparticles 
with polysorbate 80 as surface coating and the authors suggested the toxicity of 
doxorubicin loaded nanoparticles were similar or even lower than that of pure 
doxorubicin. By investigating the mechanisms of how PBCA nanoparticles deliver drugs 
across BBB, Kreuter et al. also suggested there was no toxicity effect of nanoparticles on 
BBB (Oliver, et al., 1999; Gelperina et al., 2002; Kreuter et al., 2003). 
Table 2.4 Summary of drug loaded biodegradable nanoparticles across BBB 
  NP Matrix       Drug       Surfactant        Size(nm)              Results                
   PBCA           dalargin     tween 80            260       increased latency by 50% in analgesia  
                                                                                  study (Schroder et at., 1996) 
 
   PBCA           loperamide tween 80          290        increased latency by 60% in analgesia 
                                                                                  Study (Alyautdin et al., 1997) 
 
   PBCA           doxorubicin tween 80         270        ~6mg drug/g brain at 2-5 hours, vs.  
                                                                                  0 without carriers (Gulyaev et al., 1999) 
    
   stearic acid    doxorubicin Epikuron 200   90         ~1/4 of plasma with drug after 4 hour 
                                                                                   vs.0 in brain without carrier(Fundaro, 
                                                                                   et al., 2000) 
 
  Emulsifying         --         PEG-thiamine    67          65% injected does (ID) in circulation,     
  Wax & Brij 78                                                          0.5% ID in brain after 6 hours via i.v. 
                                                                                   injection, facilitated binding to BBB 
                                                                                   thiamine transporters, no significant 
                                                                                   enhance in brain uptake (Lockman, 
                                                                                   et al., 2003) 
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PLA            FITC-dextran   tween80    ~200           observed fluorescence in rat brain 
                                                                                   after i.v. injection of fluorescent 
                                                                                   dextran loaded NPs (Sun, et al,2004) 
 
Emulsifying    paclitaxel       tween 60   ~60            significant increase in brain uptake in 
Wax & Brij 78                                                           in vitro cell line experiment & in situ 
                                                                                  brain perfusion. ( Koziara et al., 2004) 
 
Apart from polysorbate surface coatings such as polysorbate 20, 40, 60, 80, 85, many 
other coatings have also been tried by researchers such as PEG, poloxamer 407, 
poloxamer 338, polaxamer 188 (Borchardt, 1994). Although they showed prolonged 
circulation and increased uptake in in vitro BBB models, they failed to have the same 
effect in in vivo systems (Chen, et al., 2004). 
To date, the exact mechanism of nanoparticles across BBB hasn’t yet been known. 
However, it is highly possible that nanoparticles may be endocytosed or transcytosed 
through endothelial cells. Polysorbate 80 is believed to be an anchor of Apo E protein 
which can help nanoparticles mimic lipoproteins and interact with LDL receptors in 
endothelial cells leading to their uptake by brain endothelial cells (Kreuter, 2004). 
2.4 Magnetic Resonance Imaging (MRI) and MRI Contrast Agent 
2.4.1 Basic Principles of MRI 
Magnetic resonance imaging (MRI) is to apply the phenomenon of nuclear magnetic 
resonance (NMR) to the field of imaging. The first MRI test was made in 1977, four 
years after the first NMR image was obtained by Paul Lauterbur. MRI is a technique that 
relies on the inherent magnetic properties of molecules in the body. Protons from water 
molecules will shift their orientations and form a net magnetization vector when a strong 
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static magnetic field B0 is applied to the body. A radiofrequency (RF) pulse, which 
ranges from approximately 10 to 200MHz, is used to knock some of the protons out of 
alignment. Weak radio signals will be released by protons as they shift back to their 
aligned position after the radio transmitter is turned off. Different tissues will have 
different strength and duration of these signals, thus the quantity of water in each tissue 
can be determined. Then the computer will use different slices to generate a 3D image. 
Basically, an MRI system consists of a magnet assembly, RF coils, a computer and a 
display device. MRI is a safe and powerful imaging tool with high resolution and can 
detect regions that can’t be detected by other imaging tools such as CT, X-ray. MRI can 
also be used to detect tumors since it can tell the differences between normal and diseased 
tissues.  
                               
2.4.2 Important Parameters of MRI 
It is important to understand the three principal parameters of MRI: proton density (PD), 
T1 relaxation time and T2 relaxation time. They are fundamentally different from and 
independent of each other. Through changing the type of RF pulse sequence and times, 
images weighted by each of the three parameters can be obtained (Bushong, 2003). 
(1) Proton Density. Proton density, also referred to as hydrogen density, is the 
concentration of mobile hydrogen within tissues. The amplitude of the initial MR signal 
is related to the proton density in the tissue being imaged. If there is more hydrogen, 
stronger MR signal may be expected. The MR signal also depends on how hydrogen is 
bound within a molecule. The received MR signal only originates from loosely bound 
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mobile hydrogen and tightly bound hydrogen only has a weak signal. 
(2) T1 relaxation time. T1 relaxation time, which is also called longitudinal time, or spin-
lattice relaxation time, is the time needed to align protons in a static magnetic field. T1 
constant indicates the speed of the spinning nuclei to emit their absorbed RF into the 
surrounding tissues. T1 is a tissue specific time constant and the value ranges from 
milliseconds to several seconds. For example, the average T1 for soft tissue is 600ms. T1 
is longer in solids than in liquids. Generally, for T1 weighted images, tissue with short T1 
appears bright while tissue with long T1 appears dark. The reciprocal of T1, 1/T1 is 
called longitudinal relaxation rate, which can also be represented by the symbol R1 in the 
unit of ms-1. The slop of R1 over contrast agent concentration is called longitudinal 
relaxivity. 
(3) T2 relaxation time. T2 relaxation time is transverse time, or spin-spin relaxation time, 
which is the time needed for protons to lose their coherent energy in an NMR 
measurement. T2 represents a loss of transverse magnetization. T1 and T2 are 
independent; however, T2 relaxation time never exceeds T1 in a given tissue. Generally 
speaking, for T2 weighted images, tissue with short T2 appears dark while tissue with 
long T2 appears bright. Similarly, 1/T2 equals the transverse relaxation rate R2 and the 
slop of R2 over contrast agent concentration is called transverse relaxivity. 
Besides the three parameters above, T2* is often used to combine the real T2 of tissues 
and the magnetic field inhomogeneities. 
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2.4.3 Introduction to MRI Contrast Agent 
The addition of contrast agent by injection before or during MRI procedure can improve 
the sensitivity and specificity of the images obtained. Briefly, there are two kinds of 
contrast agent: positive contrast agents and negative contrast agents (MRI technology 
website). 
(1) Positive contrast agents (appearing bright on MRI). They are typically small 
molecular weight compounds containing gadolinium, manganese or iron as active 
elements which have unpaired electron in outer shells. They act predominantly on T1 
relaxation, which results in signal enhancement. The most common and commercial 
available products of positive contrast include Gadopentate dimeglumine (Gd-
DTPA), Gadoterate meglumine (Gd-DOTA), Gadodiamide (Gd-DTPA-BMA) etc. 
Gd-DTPA received approval from FDA in 1988 (Runge, 2000) and has been widely 
used in neuron and whole body imaging. Fig 2.6 below shows the chemical structure 
of Gd-DTPA from Sigma with a molecular weight of 547.57. 
 
(2) Negative contrast agent (appearing dark on MRI). They are small particulate 
aggregates often termed superparamagnetic iron oxide (SPIO). They act 
predominantly on T2 relaxation, which results in signal reduction. However, particles 
smaller than 300nm also produce substantial T1 relaxation. Fig 2.3 below also gives 
the chemical structure of a widely used negative contrast agent Fe3O4-dextran. 
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                    Fig 2.3 Chemical structures of Gd-DTPA and Fe3O4-dextran 
In addition, macromolecular paramagnetic contrast agents, ultrasmall superparamagentic 
iron oxide (USPIO) particles are also studied world wide in multicenter clinical trials. 
Runge et al. had an excellent review on contrast agent used in brain disease (Runge et al., 
1997). Moreover, a wide variety of vector and carrier molecules, including antibodies, 
peptides, proteins, polysaccharides, liposomes and nanoparticles have been developed to 
deliver magnetic labels to specific sites (Schmiedl et al.,1989; Wang et al., 1990; Runge, 
2001; Morel et al., 1998; Faranesh et al., 2004). Recently, some groups begin to do 
research on gadolinium loaded nanoparticles not only for imaging but also for neutron 
capture therapy since gadolinium itself has effect on tumor cells (Shikata et al., 2002; 






Materials and Methods 
3.1 Materials 
Paclitaxel was purchased from Dabur India Limited, India and Hande Biotechnology Inc. 
(Kunming, China). Poly (D,L-lactide-co-glycolide) (PLGA, 50:50, MW 40000-75000), 
Cormarin-6, polyvinyl alcohol (PVA, MW 30000-70000), Gadolinium 
Diethylenetriaminepenta-acetic Acid (Gd-DTPA, MW 547.57), MTT([3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]), Trypsin-EDTA and gelatin 
(type B, 225 bloom), Hank’s Balanced Salt Solution (HBSS), Penicillin Streptomycin, 
Dulbecco's Modification of Eagle's Medium (DMEM), and Phosphate Buffer Solution 
(PBS)  were purchased from Sigma-Aldrich Chemical Co., Singapore. Vitamin E 
succinate with polyethylene glycol 1000 (Vitamin E TPGS) was provided by Eastman 
Chemical Company (TN, USA). DPPC (1,2-dipalmitoyl-sn-glycerol-3-
phospatidylchlorine) was purchased from Avanti Polar Lipid, Inc. (Alabaster, A1, USA). 
Tween 80 was provided by ICN Biomedicals, Inc. (Ohio, USA).  Commercial fluorescent 
polymer microsphere suspension or dyed polymer microsphere suspension (polymers 
include polystyrene (PS), polystyrene divinylbenzene (PSDVB), or other styrene 
copolymers) was bought from Duke Scientific Corporation (CA, USA). Dichloromethane 
(DCM, analytical grade) and acetone were purchased from Mallinckrodt Company (MO, 
USA). Acetonitrile for HPLC/ Spectro use (FW=41.05) was purchased from Tedia 
Company, Inc (Fairfield, OH, USA). Madin-Darby canine kidney (MDCK) epithelial cell 
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line was purchased from American Type Culture Collection (Manassas, VA, USA) and 
passages 58-70 were used. Rat glioma cell line C6 was also purchased from the same 
company. Fetal calf serum was purchased from Hyclone Company (UT, USA). Mounting 
medium was provided by Dako Corporation (CA, USA). PI (propidium iodide) was 
purchased from Molecular Probes, Singapore. Triton® X-100 was purchased from BDH 
limited (Poole, England). Male Sprague Dawley rats, 180-220 gm each and 6-8 week old, 
were supplied by the Laboratory Animals Centre of Singapore and maintained at the 
Animal Holding Unit of NUS. Deionized water produced by Millipore (Millipore 
Corporation, Bedford, OH, USA) was used throughout the whole experiment. MPEG-
PLA was provided by Mr. Dong Yuancai and Mr. Zhang Zhiping.  
3.2 Methods 
3.2.1 Preparation of Nanoparticles 
3.2.1.1 Preparation of Paclitaxel/fluorescence Loaded Nanoparticles- Single 
Emulsion 
The PLGA nanoparticles were prepared by the oil-in-water solvent evaporation/ 
extraction technique. Altogether three samples were prepared: PVA emulsified 
nanoparticles, PVA &DPPC emulsified nanoparticles, vitamin E TPGS emulsified 
nanoparticles. Briefly, Paclitaxel 5.5mg and PLGA 110 mg were dissolved in 8 mL 
dichloromethane (DCM). DPPC 30mg was also dissolved in DCM. The resulted organic 
solution was then votexted for half a minute. The dissolved oil phase mixture was then 
poured slowly into the aqueous phase containing different emulsifiers (either 0.6 g PVA 
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or 36 mg Vitamin E TPGS dissolved in 120mL de-ionized water). The resulting emulsion 
was sonicated with an energy output of 25 W in a continuous mode for 90s.The formed 
oil in water emulsion was then stirred overnight at room temperature with the magnetic 
stirrer to evaporate the organic solvent (DCM). The produced nanoparticles were 
collected by centrifugation (11500 rpm, 12 min, 20°C) and washed with de-ionized water 
three times to remove excessive emulsifiers. The frozen product was then freeze-dried at 
-51 °C to get into fine powders of nanoparticles and kept in a vacuum desiccator for 
future use. 
The fluorescent nanoparticles were prepared using the same method above while 0.55mg 
cormarin-6 was used as fluorescent marker instead of paclitaxel. Since coumarin-6 was 
light sensitive, the whole process should be done in dark. 
3.2.1.2 Preparation of Gd-DTPA Loaded Nanoparticles- Nanoprecipitation  
Nanoprecipitation can be used to encapsulate both hydrophilic and hydrophobic 
substances. Briefly, 75mg polymer (PLGA or MPEG-PLA) was dissolved in 5mL 
acetone. 0.3mL Gd-DTPA (15% w/v) was suspended in the polymer solution and 
sonicated for about 20 seconds. The resulted suspension was added drop by drop using a 
syringe to 25mL water with 100mg F-68. The formed emulsion was then stirred 
overnight at room temperature with the magnetic stirrer to evaporate the organic solvent. 
The nanoparticles were collected by centrifugation (12,000rpm, 18°C, 60 min) and 
washed with de-ionized water twice to remove excessive Gd-DTPA and F-68. Finally, 
the frozen product was then freeze-dried at -51°C to get into fine powders of 
nanoparticles.. 
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3.2.1.3 Preparation of Gd-DTPA Loaded Nanoparticles- Double Emulsion 
Double emulsion is often used to encapsulate hydrophilic substances. Briefly, 75mg 
polymer was dissolved in 5mL DCM, 0.3mL Gd-DTPA (15% w/v) was then added to the 
oil phase. The resulting solution was sonicated for 40s, and then added to 30mL water 
with certain emulsifier. The water-in-oil-in-water suspension was sonicated for 90 
seconds. The formed emulsion was then stirred overnight at room temperature with the 
magnetic stirrer to evaporate the organic solvent (DCM). The produced nanoparticles 
were collected by centrifugation (11500 rpm, 15 min, 12 0C) and washed with de-ionized 
water three times to remove excessive emulsifiers. The frozen product was then freeze-
dried at -51 0C to get into fine powders of nanoparticles. 
3.2.2 Characterization of Nanoparticles 
3.2.2.1 Size and Size Distribution 
Particle size and size distribution were measured by laser light scattering system with 
particle size analyzer (90 Plus, Brookhaven Instruments, Huntsville, NY, USA) at 25ºC 
with a scattering angle of 90º. For the measurement, ~0.lmL nanoparticle suspension 
before freeze-drying was dispersed in 1 mL de-ionized water in a plastic cuvette, which 
was sonicated for 1minute. The cuvette was wiped clean and placed inside the machine 
for measurement. The laser will shine through the cuvette and take the reading. 
Information gathered would determine the mean diameter and size distribution which is 
also known as polydispersity.  
3.2.2.2 Particle Morphology 
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(a) Scanning Electron Microscopy (SEM)/Field Emission Scanning Electron   
Microscopy (FESEM) 
The particle size, shape and surface morphology of the nanoparticles prepared earlier 
could be characterized by SEM/FESEM (Jeol, JSM-5600 LV, Irfan View software).A 
small spatula of the sample was placed on to a black double-sided sticky tape, taped to 
the SEM/FESEM stud. They were then coated with platinum, performed in an Auto Fine 
Coater for 40s in a vacuum at a current intensity of 40mA (JFC-1300, JEOL, USA) 
before SEM/FESEM analysis. After SEM/FESEM captured the images, the sizes of the 
particles could be measured using Irfan view software. 
(b) Atomic Force Microscopy (AFM) 
The surface morphology and particle size could also be characterized by AFM 
(MultimodeTM Scanning Probe Microscope, Digital Instruments, USA). The 
nanoparticles were attached to double side sticky tape before atomic force microscopy 
(AFM) was conducted. Thereafter, AFM images were obtained by Nanoscope Ⅲ a 
(Digital Instrument, Santa Barbara, CA, USA) in tapping mode. The cantilever oscillated 
at its proper frequency (~300 KHz) and the driven amplitude was ~130 mV. 
3.2.2.3 Surface Charge 
Surface Charge was measured using ZetaPlusTMZeta Potential Analyzer (Brookhaven 
Instrument Corp, Holtsville, NY). Briefly, ~0.1mL nanoparticles suspension before 
freezedrying was dispersed in 1 mL water, which was followed by sonication for 1min. 
Then the mixture was poured into a plastic cuvette. The zeta potential of products was 
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measured with palladium electrodes, which was cleaned with de-ioned water before 
inserting into the cuvette. The cuvette was then placed inside the analyzer for surface 
charge analysis and the mean of the five readings was taken. 
3.2.3 Encapsulation Efficiency and Drug Entrapment 
3.2.3.1 Encapsulation Efficiency and Drug Entrapment of Paclitaxel loaded   
Nanoparticles 
This experiment was performed in triplicates using high performance liquid 
chromatography (HPLC) (Agilent LC1100) to determine the concentration of paclitaxel. 
A reverse phase Inertsil ® ODS-3 column (150x 4.6 mm i.d., pore size 5µm, GL Science, 
Tolyo, Japan) was used. 3 mg nanoparticles were dissolved in 1 mL DCM to extract 
paclitaxel from the nanoparticles. DCM was allowed to evaporate overnight. 3 mL 
acetonitrile/ water (50:50, v/v) was added and the solution was votexed for 1 min. After 
that, the sample was transferred to HPLC vials. The formulations that were used to 
calculate EE and drug entrapment were:   
Encapsulation Efficiency (EE) (%) = a/b×100; 
Drug Entrapment (%) =a/c×100 
where a is the amount of drug in nanospheres; b is the amount of drug used for 
fabrication; c is the amount of nanospheres. To avoid the influence of inefficient 
extraction, the extraction efficiency was also measured in this experiment. Briefly, certain 
amount of pure paclitaxel similar to the amount loaded in the corresponding amount of 
nanospheres and 3 mg placebo nanoparticles were dissolved in 1mL DCM. 3 mL of 
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acetonitrile/water were added and the same extraction procedure was done as described 
above. The resulting factor was 100%, which means no loss in the extraction procedure. 
3.2.3.2 Encapsulation Efficiency and Drug Entrapment of Gd-DTPA loaded 
Nanoparticles 
This experiment was studied by inductively coupled plasma-optical emission 
spectrometry (ICP-OES) and was done in triplicates. Briefly, 25 mg nanoparticles were 
dissolved in 3mL DCM and votexed for 1min. DCM was evaporated overnight. 3mL of 
Millipore water was added to extract Gd-DTPA. Then the samples were filtered by 
0.22µm filter. The concentration of Gd was determined by ICP-OES. 
3.2.4 In Vitro Release 
3.2.4.1 In Vitro Release of Paclitaxel Loaded Nanoparticles 
The release of paclitaxel from the nanoparticles was measured using high performance 
liquid chromatography (HPLC). 5 mg paclitaxel loaded nanoparticles were weighed into 
individual centrifuge tubes and suspended in 10 mL of fresh PBS (pH=7.4). The tubes 
were placed in a 37oC orbital shaker water bath and shaken horizontally at 120 min-1. The 
experiment was done in duplicates. The tubes were taken out at particular time intervals 
and centrifuged at 12000, 18oC, 18 minutes. The supernatant was removed and taken for 
in vitro release analysis. The precipitated nanoparticles were re-suspended in 10 mL PBS, 
sonicated, vortexed and placed back into the water bath shaker. Paclitaxel in the 
supernatant was extracted in 1 mL DCM in a separation funnel. The funnel was shaken 
consistently and 2 layers would form. The top layer contained water while the bottom 
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layer contained DCM and the extracted paclitaxel. DCM was collected and allowed to 
evaporate overnight. 3 mL of acetonitrile/ water (50:50,v/v) was added after evaporation 
and conditions for HPLC analysis were the same as mentioned above. Similarly, the 
extraction recovery coefficient was also measured using the same method mentioned 
above except that paclitaxel was in aqueous phase instead of dissolving in DCM directly. 
The extraction factor was around 80% and the data obtained for in vitro analysis was 
corrected accordingly. 
3.2.4.2 In Vitro Release of Gd-DTPA Loaded Nanoparticles 
This experiment was done in a similar way as the in vitro release of paclitaxel loaded 
nanoparticles. Briefly, 30mg nanoparticles were suspended in 5mL PBS. At pre-
determined time the samples were centrifuged and the supernatant was taken out for 
analysis. Since the Gd-DTPA released much faster than paclitaxel, the release file was 
obtained within 48 hours. The resulted released gadolinium in PBS was measured 
directly by ICP-OES. The study was also carried out in duplicates. 
 3.2.5 Cell Line Experiments 
3.2.5.1 Cell Culture 
The glioma cells C6 and MDCK were grown in 25 mL flasks, and maintained in a 
humidified 5% CO2/95% air incubator at 370C in medium (DMEM+10% FBS+5% 
penicillin G). The medium was changed every two days until the cells reached 80-90% 
confluence. After that, the cells were harvested with trypsin.  
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3.2.5.2 Trypsinization Procedures of the Cells 
The aim of trypsinization was to detach the cells from the bottle wall and collect the cells 
to transfer to the 96-well plate and estimate the density of the cells. Cells seeded in 
culture flasks were observed every 2 days, culture medium were changed every 2 days till 
cells reached ~85% confluence. The PBS and medium were warmed in the 37oC water 
bath. Trypsin should not be warmed up as heat could inactivate the enzyme. The medium 
was removed from the culture flask and the flask wall was washed with 5 mL PBS twice. 
1 mL trypsin was added to the bottle and shaken gently before removing them. Then 1 
mL trypsin was added again and incubated for about several minutes at 37oC, 5% CO2 
until detached cells were seen floating in trypsin. 5.5 mL medium was introduced to the 
bottle and pipette was used to make the cells even distributed. It was then transferred to a 
small centrifuge tube and centrifuged 800rpm, 6 minutes. The supernatant was discarded 
and the pellets were evenly suspended in 4.5 mL medium. 100µl cell suspension was 
taken out to estimate the density under the microscope. The cell density is: the sum of the 
cells in the four squares (4x4)/4*104cells/mL.  
3.2.5.3 Cell Viability Study/Cytotoxicity Study 
Cell viability/cytotoxicity study can be done with the MTT assay. The aim of this study 
was to measure quantitatively how much cells would be killed with the drug-loaded 
nanoparticles. Cell viability of nanoparticles with no drug and pure drug should also be 
tested as control. First, seed cells on 96 well plate (seeding density=1.3x104 cells/well) 
and wait for cells to grow until 80% confluence. Then, HBSS (Hank’s Balanced Salt 
Solution) stock with H2O and PBS [since both HBSS and PBS are concentrated (10x), 
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need to dilute using 1 part of HBSS to 9 part of PBS (1 part of PBS to 9 part of Millipore 
water)] was prepared. The cells with prepared HBSS medium were equilibrated and 
incubated for 1 hour. Then the HBSS was removed and nanoparticle suspensions, pure 
drug solution in DMEM were added. After incubating for a pre-determined time, the 
suspension was removed and washed with PBS twice. MTT solution was prepared by 
diluting concentrated MTT with PBS to 5mg/mL. MTT is light sensitive, henceforth must 
protect the stock bottle from light. After that, 90µl DMEM medium and 10µl MTT were 
added into the plate. The cells were incubated for 4 hours. After which, purple ppt was 
seen. Remove the media without removing the bluish ppt. Then dissolve the ppt with 
DMSO solution of 200µl each well. After that, the plate was placed inside a micro-plate 
reader and read the absorbance using 560 nm filter.  
3.2.5.4 Cell Uptake Study 
The aim of the cell uptake study was to find out how much fluorescence loaded 
nanoparticles would be taken by the cells. The previous step was similar to the procedure 
taken by the viability study until the cells had been treated with HBSS and incubated for 
1hour. In the mean time, nanoparticles with different sizes and different surface coatings 
were prepared and suspended in Millipore water. The particle suspensions were sonicated 
so that the particles would not settle at the bottom. The experiment on the 96 well plate 
was planned to include negative controls (cells only with no particles added), positive 
controls and samples. HBSS was then removed from the wells and incubated with 100 µl 
of the particle suspensions added to designated wells for 4 hours at 37oC. After 
incubation, particle suspensions and HBSS were removed only from the sample wells and 
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from the cell-only wells respectively. The cells in the sample wells and negative control 
wells were washed 3 times with PBS, mainly to remove excess nanoparticles that were 
not taken up by the cells. To the positive controls which should equivalent to 100% initial 
particle suspension seeded, 50 µl of triton/0.2M NaOH were added. 50µl PBS and 50 µl 
0.5% triton/0.2 M NaOH were added to the samples and cell-only wells. The plate was 
then scanned with a microplate reader (excitation wavelength 430 nm, emission 
wavelength 485 nm) to measure the amount of fluorescence in each well.   
3.2.5.5 Fluorescence Microscopy and Confocal Study 
The aim of fluorescence microscopy and confocal study was to give direct evidence that 
nanoparticles had really come into the cells. The MDCK cells were seeded in the 24-well 
assay white plate with coverglass seated in each well. The cells were incubated at 37oC, 
5% CO2. The medium was changed every two days until the cells reached 70% 
confluence for all wells. When the required confluence was reached, the medium was 
removed from the plate and replaced with 500µl fresh HBSS. Cells were equilibrated by 
incubating at 37oC, 5% CO2 for 1 hour. In the mean while, certain concentration 
nanoparticles were prepared and suspended in HBSS. The particle suspensions were 
sonicated so as to ensure even distribution and the particles did not settle at the bottom. 
HBSS was then removed from the plates and incubated with the particle suspension for 4 
hours. After incubation, the particle suspension and HBSS were removed from each well. 
500µl ethanol was added to fix the cells. Then the plate was placed in the incubator for 
20 minutes. After that, the ethanol was removed and the cells were washed with PBS for 
3 times. 200µl PBS was re-added and 20~30µl propidium iodide (PI) was added to stain 
the nucleus. The plate was placed in the incubator for another 40 minutes. After 
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incubation, PI was removed and the wells were washed with PBS for three times. 2~3 
drops of mounting medium were added to the cells. At last, cells could be examined 
under the fluorescence microscope or confocal microscope (Zeiss LSM 410, Germany) 
equipped with imaging software, Fluoview FV300. 
3.2.6 Animal Study 
Healthy rats were divided into three groups in in vivo experiments. One group was treated 
as control and would inject only 0.9%(w/v) NaCl saline. In the other two groups, the rats 
were intravenously injected with fluorescent nanoparticle solutions coated or uncoated 
with tween 80. After injection, the rats would be placed in the cage for 1.5 hours and the 
blood vessels of the rats would be rinsed before sacrificing them to bring out the brain. 
The bought-out rats’ brains were put into 4% paraformaldehyde solution to be fixed. 
After that, tissue freezer was used to freeze the brain tissues.  Cyrostat (Leica, CM3050) 
was used to cut the tissue into slices of 10 µm thick. The resulted slices would be 
observed under fluorescence microscopy. 
3.2.7 MRI Characterization  
The MRI characterization of Gd-DTPA encapsulated nanoparticles and the calibration 
curve of pure Gd-DTPA were measured on a 1.5T scanner with a head coil using a 
clinical MRI machine, National University Hospital (SIMENS). Briefly, Gd-DTPA 
encapsulated nanoparticle samples of a certain concentration and standard Gd-DTPA 
solution ranging in concentrations from 0 to 2mM were prepared both in water and in 
gelatin. Then they had a MR scanning with the following parameters: slide thickness = 
 39
5mm, TR ranging from 25ms to 6400ms, TE=12ms, FOV=180 and FOV phase= 100%. 
The surrounding temperature remained at 22oC in all experiments to reduce the effect of 
temperature dependence on relaxation rate. Signal intensities were measured from a 
region of interest in the center of the samples and would be transferred through a self-
developed program by NUH staff to get the corresponding T1, T2 values. Then their 
characteristics were analyzed.  
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Chapter 4 
In Vitro Study of Paclitaxel Loaded PLGA Nanoparticles to 
Treat Brain Cancer Cells 
4.1 Novel Formulation of PLGA Nanoparticles with Natural Emulsifiers 
Emulsifiers, also known as surfactants, play an important part in the process of 
fabricating nanoparticles. The emulsifier serves to ‘link’ up the oil phase and the aqueous 
phase during the formulation process (Mu and Feng, 2002). This linkage between the two 
immiscible phases stabilizes the emulsion and allows the formation of nanoparticles. This 
emulsion is possible since the emulsifier, which contains both hydrophilic and 
hydrophobic parts, helps to stabilize the dispersed or dissolved polymer and drug 
molecules by keeping them ‘apart’ and hence prevents the aggregation of these particles. 
Moreover, the remaining emulsifiers on the nanoparticle surface serves as surfactant may 
further affect nanoparticles’ characteristics.  
Compared with traditional chemical emulsifier PVA, novel natural emulsifiers vitamin E 
TPGS and DPPC have more advantages. Both of them are natural surfactants which are 
biocompatible and do no harm to human body while residual PVA on the nanoparticles’ 
surface may cause some side effects. Moreover, both vitamin E TPGS and DPPC have 
amphiphilic structures, which make them good candidates to act as emulsifiers and 
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    Fig 4.1 Chemical structure of PVA, vitamin E TPGS and DPPC 
 
Vitamin E TPGS is a water-soluble derivative of natural vitamin E, formed by 
esterification of vitamin E succinate with polyethylene glycol 1000. It has dual nature 
with part of the molecule showing hydrophobicity while another part showing 
hydrophilicity. From Fig 4.1 above, it can be seen that the polyethylene glycol portion 
(indicated in the circle) acts as the hydrophilic polar head and the tocopherol succinate 
portion (on the other end) behaves as the lipophilic tail. Vitamin E TPGS can not only 
dissolve well in water but also in oil. This special structure property suggests its potential 
application as emulsifier. Unlike PVA, vitamin E TPGS can form solution with water at a 
concentration of up to 20% (w/w), beyond which high viscosity liquid crystalline phases 
begin to form. However, the critical micelle concentration (CMC) of TPGS is only about 
0.02 wt% in water beyond which TPGS will begin to form micelles and continue to form 
low viscosity solutions till reach the concentration of 20%. If the concentration of TPGS 
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is too low in water, it won’t act as an emulsifier. However, if it is too high, TPGS tends to 
self-assemble to form micelles and change the state in the aqueous dispersing phase. Mu 
and Feng found that the optimal concentration for TPGS as emulsifier was 0.02%-0.03%, 
which resulted in best nanoparticle yield and size (Mu and Feng, 2003).  
In the same way, natural phospholipid DPPC also has amphiphilic structure. From the 
chemical structure of DPPC in Fig 4.1, it is clear that DPPC has a hydrophilic head (the 
part in the circle) and a hydrocarbon tail. In the following experiments, these two novel 
emulsifiers will be used to fabricate the paclitaxel/fluorescence loaded nanoparticles of 
biodegradable PLGA nanoparticles and their potential to cross the blood brain barrier and 
to treat brain tumor will also be investigated. 
4.1 Size, Size Distribution and Surface Charge  
Table 4.1 Size, polydispersity and zeta potential of 5% paclitaxel loaded PLGA     
nanoparticles with different emulsifiers 
Matrix/Emulsifier Particle Size (nm) Polydispersity Zeta Potential (mV) 
PLGA /PVA 267.3 0.076 -13.80 
PLGA/DPPC&PVA 245.2 0.066 -15.70 
PLGA/vitamin E TPGS 284.8 0.048 -28.82 
Table 4.1 above shows the particle size, size distribution and surface charge of 5% 
paclitaxel loaded PLGA nanoparticles (5.5mg paclitaxel plus 110mg PLGA during 
fabrication) with different emulsifiers. Solvent extraction /evaporation (single emulsion) 
method was used to fabricate these nanoparticles.  Altogether three batches of particles 
were fabricated and would be used for further investigations including PVA emulsified 
nanoparticles, DPPC emulsified nanoparticles with PVA as co-emulsifier in water phase 
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and vitamine E TPGS emulsified nanoprticles. The particle size and polydispersity were 
determined by LLS (laser light scattering). Zeta potential was determined by zeta 
potential analyzer. From the table, it can be seen that nanoparticles with size less than 
300nm and a negative surface charge were achieved.  
4.2.1 Particle Size and Size Distribution 
Prior to fabricating the DPPC emulsified nanoparticles with PVA as co-emulsifier, the 
effect of DPPC alone as emulsifier both in water phase and oil phase was also 
investigated. Although DPPC possesses amphiphilic structures, it doesn’t dissolve very 
well in the water phase, which reduces the effectiveness of its emulsifying efficiency. 
The size of the particle with DPPC as emulsifier in water phase was around 1700nm. 
Usually, nanoparticles for drug delivery to the brain are of diameter less than 400nm 
(Chen et al., 2004). Therefore it was not favorable for the purpose of crossing BBB. 
Although DPPC can dissolve well in the oil phase, the particle size of DPPC as emulsifier 
in the oil phase was still as much as 1000nm, which was still too large for our 
investigation purpose. The large particle size may be caused by the relative small 
molecular weight of DPPC which is only 734. Finally, we used DPPC as emulsifier in the 
oil phase and PVA in the water phase as co-emulsifier.  From Table 4.1, it is clear to see 
that nanoparticles fabricated by this way not only has favorable size but also has good 
surface characteristics.  
From table 4.1, it can also be seen that DPPC & PVA emulsified nanoparticles have a 
smaller particle size than that of naked PVA emulsified nanoprticles. The results may be  
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due to the additive effect of co-surfactant (Kreuter, 1994). The combination of PVA and 
DPPC increases the emulsifying efficiency, thus makes smaller size of the nanoparticles. 
Moreover, the polymer matrix PLGA was also dissolved in the oil phase; DPPC served 
not only as emulsifier but also part of the matrix and would affect nanoparticles’ surface 
characteristics.  
Vitamin E TPGS emulsified nanoparticles have a larger particle size than other two 
formulations. This may be due to the differences in the chemical structure of TPGS and 
PVA. From Fig 4.1, it can be seen PVA has a long linear chain structure with a high 
molecular weight up to 30,000-70,000, which makes it an effective emulsifier in 
stabilizing the oil droplets to form small nanoparticles. However, the molecular weight of 
vitamin E TPGS is only 1,513, which is less than 1/20 of that of PVA, thus makes TPGS 
emulsified nanoparticles have larger particle size. However, considering the amount of 
TPGS used in the fabrication (36mg) compared with PVA (600mg), we can still think the 
emulsifying efficiency of vitamin E TPGS is higher than that of PVA.  
The size distribution was measured by laser light scattering system. In this system, the 
size distribution was specified in the light scattering intensity and polydispersity was 
defined as the log normal distribution width of the particle diameter. From Table 4.1, it 
can be seen that for all the three formulations, a narrow size distribution of 0.048~0.076 
was achieved, which means the size of the nanoparticles is very uniform. This point can 
also be further confirmed by the SEM pictures shown below. 
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4.2.2 Surface Charge Study 
Zeta potential is an indicator of nanoparticles’ surface charge, which also determines the 
stability of nanoparticles in dispersion. Moreover, zeta potential can affect the 
characteristics of tissues. Lockman et al discovered recently that cationic and high 
concentration anionic nanoparticles would disrupt the integrity and permeability of the 
blood brain barrier while neutral and low concentration anionic nanoparticles would not. 
Thus only neutral and low concentration anionic nanoparticles were suitable to be used as 
drug carrier to the brain. They also discovered that the brain uptake rates of low 
concentration anionic nanoparticles were superior to that of neutral and cationic 
formulations at the same concentration (Lockman et al., 2004). 
The surface charge of nanoparticles was measured by the Brookhaven zeta potential 
analyzer in this project. From Table 4.1, it could be seen that all three batches of 
nanoparticles were negatively charged which were suitable for brain uptake in low 
concentrations. The negative surface charge could be attributed to the presence of ionized 
carboxyl groups on nanoparticles’ surface (Sahoo et al., 2002). Stolnik et al. reported that 
the zeta potential of naked PLGA nanoparticles without any PVA in neutral buffers was 
about -45mV (Stolnik et al., 1995). This high negative charge was primarily due to the 
uncapped end carboxyl groups of the polymer at particle surface. 
 Our samples showed a much lower negative charge than naked PLGA. For PVA 
emulsified nanoparticles, the zeta potential was -13.80mV, DPPC&PVA emulsified 
nanoparticles was -15.70mV, vitamin E TPGS emulsified nanoparticles was –28.82mV. 
The reduction in negative charge on particle surface should be attributed to the shielding 
 46
effect of the remaining emulsifier on particle surface which serves as surface coating or 
surfactant. Coating nanoparticles with these amphiphilic materials shields the surface 
charge and moves the shear plane outwards from the particle surface (Sahoo et al., 2002). 
It was found that a fraction of PVA used as emulsifier would form a stable inter-
connected network with the polymer at interface during nanoparticle fabrication and 
would not be removed via the washing process (Carrio et al., 1991; Boury et al., 1995). 
For DPPC, because of its relative low solubility in water and blending with polymer in 
the oil phase during fabrication, a considerable fraction of it will also be remained in the 
particle surface. Feng & Huang found a dominant DPPC remained in DPPC emulsified 
nanoparticle surface using XPS (X-ray Photon Spectroscopy) detection (Feng and Huang, 
2001). For vitamin E TPGS emulsified PLGA nanoparticles, they had a higher negative 
zeta potential than the other two batches but still lower than that of naked PLGA 
nanoparticles. This may due to the good solubility of TPGS in water and the small 
amount used (only 36 mg compared with 600mg PVA) during fabrication so that they can 
be relatively easily washed away. However, the lower negative zeta potential of vitamin 
E TPGS emulsified nanoparticles than naked PLGA nanoparticles indicates the existence 
of remaining TPGS on particle surface.  
4.3   Surface and Bulk Morphology 
Besides size, size distribution and surface charge, surface and bulk morphology of 
nanoparticles is also very important because it determines the drug release kinetics from 
the nanoparticles. Scanning electron microscopy (SEM) and atomic force microscopy 
(AFM) in tapping mode were used to give both general and specific morphology of the 
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nanoparticles. SEM needs prior coating of platinum on the surface of nanoparticles and 
can demonstrate morphology of bulk nanoparticles. As the voltage of instruments 
decreases, SEM images of higher amplification can be achieved without damaging the 
samples. In contrary to SEM, AFM doesn’t need sample coating and can provide much 
higher resolution than SEM, thus more detailed surface morphology can be achieved. 
AFM can also demonstrate 3-D morphology of the nanoparticles.  
Fig 4.2 to Fig 4.4 demonstrates the SEM and AFM images of all three batches of 
nanoparticles. From SEM, it can be seen that all nanoparticles had fine spherical shapes 
and smooth surfaces. There were some club-shaped things among nanoparticles, which 
was the drug that hadn’t been encapsulated but remained on the surface of nanoparticles. 
AFM reveals the fine structures of nanoparticle surface and clear 3-D morphological 
images of spherical nanoparticles.  It can also be seen that there was no aggregation or 
adhesion among nanoparticles. Although the multi-particle AFM images showed smooth 
surface as seen below, some researchers have done single particle zoom in (Mu & Feng, 
2003) and particle sectioning analysis (Feng & Huang, 2000), which substantiated the 
existence of complex topography of nanoparticles indicating  micro-caves and pores on 
the surface instead of simple smooth morphology. Though the structure of the 
nanoparticles could be quite complex, the relative smooth surface could be shown as an 
evidence to support the assumption that the release of drug from nanospheres might be 
caused by both polymer erosion and drug diffusion.  
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Fig 4.2 SEM and AFM images of PVA emulsified PLGA nanoparticles (5% drug loading) 
 
              
Fig 4.3 SEM and AFM images of PVA & DPPC co-emulsified PLGA nanoparticles (5% 
drug loading) 
 
Fig 4.4 SEM and AFM images of vitamin E TPGS emulsified PLGA nanoparticles (5% 
drug loading) 
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4.4     Encapsulation Efficiency of Paclitaxel Loaded Nanoparticles 
Encapsulation efficiency (EE) is the parameter to characterize the fraction of drugs 
incorporated into the nanoparticles compared with the original amount used in fabrication. 
EE is important in developing drug carriers since too low EE will prevent the mass 
production of drug loaded devices, especially for those expensive drugs such as paclitaxel. 
In this experiment, high performance liquid chromatography (HPLC) was used to 
measure the encapsulation efficiency of paclitaxel in PLGA nanoparticles and the 
experiment was done in triplicate.  
From Fig 4.5 below, we can see all three batches of nanoparticles obtained favorable EE 
value. For PVA emulsified nanoparticles, the encapsulation efficiency was 58.42%, for 
DPPC&PVA emulsified nanoparticles, EE value was 45.71% and the encapsulation 
efficiency of vitamin E TPGS emulsified nanoparticles was 92.30%. The relative high 
encapsulation efficiency is attributed to the physiochemical characteristics of the drugs 
encapsulated. During the process of forming solid nanoparticles with 
extraction/evaporation method, not only organic solvent, but also the polymer and drug 
will partition or diffuse from internal organic phase to external aqueous phase, which 
results in the loss of drugs. Just as introduced previously, paclitaxel is very hydrophobic, 
thus most of it would stay in the polymer matrix even after repeated washing during 
fabrication. For hydrophilic drugs, the encapsulation efficiency won’t be that high with 
the same extraction/evaporation method (Jain, 2000). 
Besides the drug encapsulated, EE is also influenced by the polymer, the emulsifier, the 
method used to fabricate nanoparticles and the particle size. Generally, the larger the 
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particles, the higher the encapsulation efficiency and our result is correspondent with this 
principle. Vitamin E TPGS emulsified nanoparticles had the largest particle size and they 
also had the highest EE value. On the other hand, DPPC& PVA emulsified nanoparticles 
had the smallest particle size and they got the smallest encapsulation efficiency. 
From Fig 4.5, we can also discover that the encapsulation efficiency of vitamin E TPGS 
emulsified nanoparticles is much higher than the other two batches. Although size may 
affect EE as discussed above, other factors such as the effect of emulsifiers must also be 
considered for this significant improvement. Vitamin E TPGS has large and bulky 
surface areas in its hydrophilic polar head portion and lipophilic alkyl tail, which might 
account for its effectiveness in preventing the partition or diffusion of hydrophobic 
paclitaxel from internal polymer matrix to external phase. The high encapsulation 
efficiency of vitamin E TPGS emulsified nanoparticles also improves the current solvent 












Fig 4.5 Encapsulation efficiency of PVA, DPPC and vitamin E TPGS emulsified PLGA 
nanoparticles(5% paclitaxel loading, n=3) 
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4.5     In Vitro Release Profile of Paclitaxel from Nanoparticles 
One of the greatest advantages of applying nanoparticles as drug delivery device is the 
possibility of achieving “controlled release”. By releasing drugs in a sustained manner, 
the drug concentration will be maintained within therapeutic index thus to reduce 
administration times and prolong the action of drug molecules. In vitro release kinetics is 
a very important parameter to measure the drug loaded devices.  
Fig 4.6 shows the in vitro release profile of the three batches of nanoparticles after 
corrected with the extraction efficiency factor. The experiment was carried out in the 
phosphate buffer solution (PBS) of pH=7.4 at 37oC in an orbital shaker as the simple 
simulation of human body environment. Release in about 1 month was measured. All 
batches of nanoparticles had a similar release profile with an initial burst in the first few 
days and later slow and sustained release in a nearly constant rate. For PVA emulsified 
nanoparticles, the initial burst was quite high with over 40% of drugs in the first three 
days; for DPPC&PVA emulsified nanoparticles, the initial burst was around 30% while 
vitamin E TPGS emulsified nanoparticles had the smallest initial burst of  less than 20%. 
After 25 days, PVA emulsified nanoparticles released around 68% of all encapsulated 
drugs; DPPC& PVA emulsified nanoparticles released around 60% and vitamin E TPGS 
emulsified nanoparticle released the least percentage of around 40%. However, we can 
not say vitamin E TPGS emulsified nanoparticles released the least amount of drug since 
the encapsulation efficiency of it is much higher. 
Recall the SEM pictures, not all drug molecules have been encapsulated into the 
nanospheres, there were some on the surface of the nanoparticles. The initial burst could 
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be caused by the diffusion release of paclitaxel distributed on or near the surface of 
nanospheres. Afterwards, the release rates slowed down because it needed time for 
paclitaxel to diffuse out from relative inner shell of nanoparticles. Swelling of the 
nanoparticles, which was caused by the absorption of the PBS solution, could also have 
occurred, leading to the release of drugs via dissolution. Since the degradation of 
polymers is very slow, the main mechanisms for drug release should be diffusion and 
matrix swelling. 
The differences in initial burst and releasing rate of the three batches of nanoparticles 
may be caused by different properties of the emulsifiers. The addition of DPPC in 
fabrication formed a layer of coating on nanoparticles’ surface, thus reduced the micro-
caves and micro-pores on nanoparticle surface. Therefore, both the initial burst and 
release rate decreased for DPPC&PVA emulsified nanoparticles compared with naked 
PVA emulsified nanoparticles. Although smaller particles usually result in faster 
releasing rate, the DPPC&PVA emulsified nanoparticles with smaller particle size still 
had slower rate than PVA emulsified nanoparticles because the effects of emulsifier 
dominated over the releasing procedure.  For vitamin E TPGS emulsified nanoparticles, 
firstly, their relative large particle size resulted in slower release rate; secondly, the 
ability for TPGS to dissolve well in both water and oil phase together with their bulky 
chains helped PLGA and paclitaxel have better interaction in fabrication thus further 
reduced the releasing rate. Although neutral PBS can act as a simple simulation of human 
body, it could not replace the real in vivo situation. Different pH values, ions and various 





























Fig 4.6 In vitro release profile of PVA, DPPC, vitamin E TPGS emulsified nanoparticles 
(5% paclitaxel loading)   
 
4.6     Cell Culture of Rat Brain Tumor Cell Line C6 
C6 is a kind of rat glial tumor cell line, which was used as a model cell line to study the 
cell viability in this project. Fig 4.7 below is the image of C6 cell line after 3 days’ 
culture. This picture was also taken with the Olympus 1X700 optical microscope in 
chemotherapeutic engineering lab, NUS.   
 54
                     
Fig 4.7 Morphology of rat brain glioma cell line C6 reaching ~50% confluence after ~ 3 
days’ culture 
4.7     Cell Viability Study 
To evaluate the potential of paclitaxel loaded nanoparticles to treat brain cancer, cell 
viability study was carried out using MTT assay with rat brain cancer cell line C6 as the 
model cell line. MTT assay is a laboratory test for measuring cellular proliferation (cell 
growth). MTT is added to a cell culture and is modified into a dye by enzymes associated 
metabolic activity in a live cell.  The cell viability of commercial paclitaxel product 
Taxol® was also tested to do a comparison with the paclitaxel loaded nanoparticles.  
Fig 4.8 and Fig 4.9 show the concentration effect and time effect in cell viability study of 
paclitaxel loaded nanoparticles and Taxol®. The initial drug loading was 5%. In the 
concentration study, three concentrations of loaded paclitaxel or Taxol® were tested: 
0.25µg/mL, 2.5µg/mL and 25µg/mL. The cell viability of corresponding placebo 
nanoparticles was also tested as control. The incubation time for this study was 24 hours. 
For the time effect study, the drug concentration remained at 0.25µg/mL while the 
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incubation time varied from 24 hours to 72 hours. Placebo nanoparticles were also tested 
in the time effect study. 
It is quite clear that with the increase of concentration and time, the cell viability 
decreases. Drug loaded nanoparticles showed a comparable effect in killing cancer cells 
of pure taxol® in the concentration and time intervals tested.  
In the concentration effect study, C6 cells had about 80% viability at the concentration of 
0.25µg/mL; when the drug concentration increased to 25µg/mL, this value decreased to 
about 60%, which indicated that concentration had much effect in cell viability. Similar 
trend has also been found by other groups using doxorubicin loaded PLGA microparticles 
(Lin et al., 2005). If the drug concentration goes to a too high value, the toxic adjuvant 
Cremophor EL of taxol® might also begin to kill cells and it will be hard to compare the 
effect of paclitaxel loaded nanoparticles and taxol®itself. Although drug loaded 
nanoparticles and pure taxol® showed comparable effect in killing C6 brain cancer cells, 
the particle formulation has more advantages considering only around 10% of the drug 
released from the particles in 24 hours in the in vitro release profile. This augment might 
be caused by the increased uptake percentage of the particles than pure taxol®. Due to the 
existence of P-gp, it is very difficult for pure drug to enter cells. However, the 
nanoparticle formulation can mask the characteristics of P-gp and easily enter the cells. 
For the time effect study, similarly, cell viability was around 80% after incubating for 24 
hours at the concentration of 0.25µg/mL. However, after 72 hours, cell viability 
decreased to only about 50% at the same concentration. It is thus can be seen longer time 
with even lower concentration may exert great effect on cell viability. This might be 
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caused by the release of paclitaxel from nanoparticles, especially in the first several days 
when the initial burst happens. We can also discover from the two figures that vitamin E 
TPGS emulsified nanoparticles have the relative lowest cell viability in different 
concentrations and time. The higher mortality of C6 cells to TPGS emulsified 
nanoparticles may be caused by the high cellular uptake of the drug loaded nanoparticles 
compared with other batches of nanoparticles and pure drug. The comparison of cellular 
uptake study will be discussed later. Moreover, the placebo PLGA nanoparticles with 
different emulsifiers all showed no cytotoxic effect on cells in this study, which indicated 
that it was the drug released not the nanoparticles themselves that killed the cells. All 
































Fig 4.8 C6 cell viability study of pure taxol, 5% paclitaxel loaded and no drug loaded 
(placebo) PLGA nanoparticles with different emulsifiers in different concentrations, 


































Fig 4.9 C6 cell viability study of pure taxol, 5% paclitaxel loaded and no-drug loaded 
(placebo) PLGA nanoparticles with different emulsifiers in different time intervals. 
Concentration=0.25 µg/mL (n=6)  
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Chapter 5 
In Vitro and In Vivo Uptake Study of Fluorescence Loaded 
Polymeric Nanoparticles to Cross the Blood Brain Barrier 
Blood brain barrier plays an important part in preventing the drug from entering the brain 
freely. The uptake experiment of fluorescent marker loaded nanoparticles through simple 
in vitro BBB model and in vivo can give direct evidence of nanoparticles’ possible ability 
to enter the brain. 
5.1 MDCK Cell Line as In Vitro BBB Model 
In this project, MDCK (Madin-Darby canine kidney), a well characterized model for 
many biological functions, was used as the simple in vitro model of the blood brain 
barrier for cell uptake experiment. This cell line is endowed with the ability to form 
polarized monolayers that express tight junctions in the apical side. MDCK cells also 
produce many of the enzymes found in the brain endothelial cells. Under appropriate 
culture condition, monolayers with tightness comparable to that found in the brain 
endothelial cells can be obtained within days of culture. MDCK monolayers represent a 
relatively simple model for the screening of compounds that are transported passively 
across the blood-brain barrier. Although other systems such as the primary brain 
microvessel cells and co-culture system are also used in BBB investigation (Borchard et 
al., 1994), it is relatively difficult to maintain these systems compared with MDCK 
system. Fig 5.1 shows the morphology of MDCK cell line of about 80% confluence after 
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5 days’ culture. This image was taken with the Olympus 1X700 optical microscope in 
chemotherapeutic engineering lab, NUS. 
                        
 
 Fig 5.1 Morphology of MDCK cell line reaching ~80% confluence after ~5 days’ culture  
 
5.2     Cell Uptake Study 
Cell uptake study is to validate the ability of nanoparticles to cross the in vitro BBB 
model.  MDCK cell line was used as a simple simulation of the in vitro blood brain 
barrier in this experiment. 
5.2.1 Surfactant Effect 
In order to test the effect of emulsifiers on cellular uptake of nanoparticles, fluorescent 
marker coumarin-6 was encapsulated into the PLGA nanoparticles with different 
emulsifiers using single emulsion method. The resulting nanoparticles had similar 
particle size, size distribution and zeta potential to the paclitaxel loaded nanoparticles. 
The quantitative uptake percentage could be obtained via microplate reader.  
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To prevent the misinterpretation of nanoparticle uptake data due to the dissociation or 
leaching of coumarin-6 directly into the cells, in vitro release of fluorescent marker was 
also carried out using microplate reader within 24 hours. It was found that less than 0.5% 
of coumarin-6 released from all batches of nanoparticles during this period. Since the 
incubation time was only 4 hours in this experiment, so the released fluorescent marker 
can be neglected. Lu et al. also detected similar low release of coumarin-6 from 
nanoparticles in vitro with different pH buffers using fluorescent column HPLC (Lu et al., 
2005). Moreover, the relative inertia of coumarin-6 encapsulated in PLGA nanoparticles 
guaranteed the dye not to leak out under the physiological conditions or under the acidic 
endo-lysosome compartment (Panyam et al., 2003). Actually, coumarin-6 encapsulated 
nanoparticles are widely used in cell uptake experiment (Khin and Feng, 2005; Davda 
and Labhasetwar, 2002; Panyam et al., 2002). 
Fig 5.2 below shows the cell uptake percentage of PLGA nanoparticles with different 
emulsifiers after 4 hours’ incubation with the particle concentration of 250µg/mL. 
Generally, 4 hours is enough for cells expressing brain structure to reach their highest 
uptake percentage (Ramge et al., 2000). 29.4% PVA emulsified nanoparticles were taken 
up by MDCK cells, the uptake percentage of DPPC&PVA emulsified nanoparticles was 
41.0% and vitamin E TPGS emulsified nanoparticles exerted the highest uptake 
percentage of up to 63.8%, which was more than 2 folds of PVA emulsified nanoparticles. 
This difference in the uptake percentage is mainly caused by the surfactant on particle 
surface. PVA is a kind of chemical surfactant and the remaining PVA on particle surface 
may reduce the intracellular uptake because it makes the particle surface more 
hydrophilic, thus becomes difficult to interact with the hydrophobic cell membrane. On 
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the other hand, DPPC is a kind of natural lipid surfactant and DPPC coated nanoparticles 
are not only nontoxic but also help to enhance the cellular uptake since the lipid has 
similar structure as cell membrane. Fenart et al. reported similar research on 
phospholipids DMPC coated nanoparticles which showed enhanced ability to cross BBB 
without degradation (Fenart et al., 1999). For vitamin E TPGS emulsified nanoparticles, 
the remaining TPGS on particle surface formed a natural surfactant layer which not only 
had enhanced interaction with cells but also inhibited the P-glycoprotein on the MDCK 
membrane surface (Dintaman and Silverman, 1999). All of these can account for the 


























 Fig 5.2 MDCK cellular uptake of PLGA nanoparticles with different emulsifiers, 
incubation time = 4 hours, concentration = 250 µg/mL. (n=6) 
 
5.2.2 Particle Size Effect 
Besides surfactant, particle size also plays a key role in adhesion and interaction with 
biological cells (Foster et al., 2001), especially for cells that express tight junctions such 
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as MDCK cell line used in this experiment. Although the PLGA nanoparticles showed 
favorable cellular uptake with their particle size within 200nm to 300nm, it is necessary 
to do further investigation on particle size effect so that we can develop more favorable 
nanoparticles for brain drug delivery. Commercial fluorescent polystyrene (PS) 
nanoparticles with various uniform sizes were used in this investigation. The tested sizes 
included 20nm, 57nm, 100nm, 200nm, 510nm. All particles had a negative surface 
charge.  The incubation time for nanoparticles was also 4 hours. Three different 
concentrations: 50µg/mL, 250 µg/mL, 500 µg/mL were used to validate the result.  
Fig 5.3 below showed the MDCK cellular uptake profile of different concentration PS 
nanoparticles with uniform sizes within 20nm~ 510nm. The fluorescent PS nanoparticles 
are suitable for the cell uptake study since the encapsulated fluorescence also releases 
very slowly and would not cause false reading (Kin and Feng, 2005). Obviously, the cell 
uptake percentage of PS nanoparticles was much lower than PLGA nanoparticles. The 
highest cellular uptake of PS nanoparticles was only about 16%. This should mainly be 
caused by different characteristics of the two polymers. Unlike PLGA, PS, which is often 
used to produce plastic bags, is not biodegradable or biocompatible. However, PS can 
produce nanoparticles with various uniform sizes, especially very small sizes, so it also 
has wide application in scientific research. Another reason for the low uptake of PS 
nanoparticles might be the lack of proper surfactant on particle surface.  
From Fig 5.3, we can see in the whole concentration range, the 57 nm PS nanoparticles 
showed the highest uptake percentage and 20nm, 500nm nanoparticles showed the lowest 
uptake percentage compared with other sizes. 100nm and 200nm nanoparticles showed 
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quite similar uptake percentage which was between the highest and the lowest. The 
results implied particle size around 60nm may have the best uptake percentage by cells 
expressing tight junctions. This might be caused by the combination of several 
mechanisms to uptake particles of this size including paracellular passage, endocytotic 
uptake and phagocytosis. It has been reported that phagocytic uptake took place with a 
cut-off size of about 500nm. For nanoparticles of lower size, they can also be taken up by 
fluid phase endocytosis (Suh et al., 1998; Foster et al., 2001).  Particle size of 500nm or 
above might be too large for drug delivery to brain.  The surprisingly low uptake 
percentage of the 20nm nanoparticles might be caused by the aggregation of the particles 
due to their too small size. The result of the experiment showed that particle size for brain 
delivery was not necessarily the smaller, the better. An optimal particle size is very 


























5.3 MDCK cellular uptake profile of fluorescent polystyrene nanoparticles with uniform 




5.3  Confocal Study 
From above studies, the cellular uptake percentage of PLGA nanoparticles with different 
emulsifiers was investigated quantitatively using microplate reader. To give direct 
evidence that nanoparticles had really come into the cells instead of just attaching to them, 
confocal laser scanning microscopy was used to visualize the internalization of 
nanoparticles. Fig 5.4 below shows the confocal images of nanoparticles into MDCK cell 
line. The nuclei of cells were stained red with PI (propidium iodide) while the 
nanoparticle had a fluorescence of green. We can see from the pictures that most 
nanoparticles had internalized the cytoplasma of the cells and vitamin E TPGS emulsified 
nanoparticles had the thickest layer of drugs internalized. No fluorescence could be 
detected by the control cells not exposed to coumarin-6 loaded nanoparticles and the 
placebo nanoparticles, which meant no false reading was caused by auto fluorescent of 
the cells or the polymers.  







Fig 5.4 Confocal images of fluorescence loaded PLGA nanoparticles with different 
emulsifiers. (a) PVA emulsified nanoparticles (b) DPPC& PVA emulsified nanoparticles 
(c) vitamin E TPGS emulsified nanoparticles 
 
 
5.4  In Vivo Study with Rat Models   
Although in vitro studies have shown great potential for PLGA nanoparticles to cross the 
blood brain barrier, it is necessary to carry out in vivo study to validate this assumption. 
Male Sprague Dawley rats of around 200g in weight were used as animal model. From 
previous study, we can see all batches of nanoparticles had favorable characteristics, of 
which vitamin E TPGS emulsified PLGA nanoparticles had the best cellular uptake in 
vitro, so it was used as model nanoparticles. Coumarin-6 was used as fluorescent marker 
due to its relative inertial property in physiologic environment and very low release rate 
mentioned previously (Panyam et al., 2003). It is also reported that polysorbate coating 
on nanoparticles plays a very important role in brain targeting and polysorbate 20, 40, 60, 
80, 85 (tween 20, 40, 60, 80, 85) are the only kinds of surface coating that can effectively 
help nanoparticles across the blood brain barrier in vivo (Kreuter, 2001). Thus the model 
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PLGA nanoparticles were overcoated with tween 80 and centrifuged to remove excess 
coatings before injecting to the animal models. 0.3 mL nanoparticle suspension in 
0.9%(w/v) NaCl saline was injected intravenously to the rat tail. After 90 minutes, rats 
were killed and their residual blood was rinsed before their brains were fixed and cut into 
tissue slices. Besides tween 80 coated PLGA nanoparticles, naked PLGA nanoparticles 
and pure saline were also injected to control rat groups. No mortality of rats was observed 
after injection of coumarin-6 loaded PLGA nanoparticles, which indicated the safety of 
using PLGA nanoparticles as drug carriers.  
The prepared brain tissue slices were observed under fluorescence microscope. Tween 80 
coated PLGA nanoparticles had significant fluorescence as shown in Fig 5.5 while the 
control groups of pure saline and naked PLGA nanoparticles injected in rat brain tissues 
showed no fluorescence under the same fluorescence intensity and exposure time. This 
indicates that the rat brain tissue has no or very weak auto-fluorescence and tween 80 is 
very important in brain targeting and crossing BBB. This result is quite correspondent 
with researches of Sun et al. who investigated the FITC-dextran loaded PLA 
nanoparticles to cross the BBB in vivo (Sun, et al., 2004).  From Fig 5.5, it was quite 
clear the blood vessels of rat brain had more fluorescence. This is easy to understand 
since the particle solution was injected through venous vessels. We can also find that the 
surrounding brain tissues were stained, which indicated the potential of nanoparticles 
across the blood brain barrier and migrated from the ‘blood’ to the ‘brain’.  Our study 
gave direct evidence of fluorescence-loaded PLGA nanoparticles to be delivered to the 
brain intravenously and had the potential to cross the blood brain barrier. 
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Fig 5.5 Fluorescence microscope image rat brain tissue after injection with tween-80 




Formulation and Characterization of Gadolinium-DTPA 
Encapsulated Nanoparticles for Potential In Vivo Imaging 
6.1 Significance to Develop MRI Contrast Agent Gd-DTPA 
Encapsulated Biodegradable Nanoparticles 
In previous studies, we used invasive histological method of tissue analysis to investigate 
the potential of nanoparticles to cross the blood brain barrier in vivo by injecting 
fluorescent marker loaded nanoparticles intravenously and observing the resulting brain 
tissue slice directly under fluorescence microscope. Other indirect methods such as tail 
flick (Alyautdin et al., 1997), hot plate (Schroeder et al., 1998) have also been adopted by 
other groups. However, all these methods can not continuously assess the delivery and 
distribution of particles in vivo. Thus it is necessary to develop a kind of noninvasive and 
continuous monitoring technique to evaluate the in vivo behavior of nanoparticles. Due to 
its high spatial and temporal resolution, magnetic resonance imaging (MRI) becomes a 
good candidate for non-invasive imaging. To enhance the MR images’ contrast, various 
contrast agents are often used, of which the chelated paramagnetic gadolinium Gd-DTPA 
is the most widely adopted due to its good effect and low toxicity.  By encapsulating the 
MRI contrast agent into the nanoparticles of biodegradable polymers, we can thus have 
the potential to achieve the monitoring of local drug delivery and release kinetics in vivo. 
And this would also greatly enhance the value of particle based drug delivery systems 
 69
(Chen et al., 2005). The following investigations tested the feasibility of encapsulating 
Gd-DTPA into biodegradable nanoparticles and their MRI characteristics in vitro.  
6.2   Size, Size Distribution, Zeta Potential Study 
 Table 6.1 Size, size distribution and surface charge of Gd-DTPA encapsulated 
nanoparticles with various formulations  
Type         Size (nm) polydispersity zeta potential(mV)
PLGA(NP*)          398.3 0.230 -18.95 
PLGA(DE*)+TPGS          3000.0 0.085 -20.34 
PLGA(DE*)+PVA          269.0 0.073 -17.13 
PLGA +salt(NP*)          234.4 0.209 -15.15 
MPEG-PLA(NP*) 
 
MPEG-PLA(DE*)       
         106.2 
 







* DE= double emulsion, NP=nanoprecipitation 
Table 6.1 summarized the particle size, size distribution and surface charge of Gd-DTPA 
encapsulated nanoparticles. Double emulsion and nanoprecipitation methods were used to 
encapsulate the hydrophilic Gd-DTPA. Besides PLGA, MPEG-PLA with PEG ratio of 
10% was also used since the existence of PEG chains made the co-polymer more 
hydrophilic and have better interactions with Gd-DTPA. Different emulsifiers PVA and 
vitamin E TPGS were also tried.  
Unlike single/double emulsion, the process of nanoprecipitation doesn’t need any 
emulsifiers to form the nanoparticle droplets. The Gd-DTPA encapsulated PLGA 
nanoparticles using nanoprecipitation had a relative larger particle size than other batches 
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of nanoparticles. However, after adding some salt such as Na2HPO4 in the water phase 
during the fabrication process, the particle size decreased a lot. This may be caused by 
the added ions and the changed pH in aqueous phase (Govender et al., 1999, Peltonen et 
al., 2004). Compared with PLGA, Gd-DTPA encapsulated MPEG-PLA nanoparticles had 
much smaller particle size of around 100nm. Dong and Feng also reported small particle 
size of paclitaxel loaded MPEG-PLA nanoparticles using nanoprecipitation (Dong and 
Feng, 2004). The smaller particle size is favorable for the purpose of crossing blood brain 
barrier just as discussed above. 
From table 6.1, we can also find emulsifiers play an important role in determining the 
particle size in the double emulsion methods, even more significant than in single 
emulsion. For PVA emulsified PLGA nanoparticles, the size was 269.0nm, which was 
comparable with the size of nanoparticles using single emulsion we developed previously. 
However, for vitamin E TPGS emulsified PLGA nanoparticles using double emulsion, 
the size was as much as 3µm. Just as discussed previously, this should be caused by the 
relative low molecular weight of TPGS, which makes it less efficient to form smaller 
particle size.  
The size distribution of all batches of nanoparticles varied from 0.073 to 0.230. Generally, 
double emulsion method resulted in a smaller size distribution than nanoprecipitation. 
We can also see from table 6.1 that all batches of nanoparticles had a negative surface 
charge and MPEG-PLA nanoparticles had smaller negative charge than PLGA 
nanoparticles. This might be caused by the presence of more carboxyl groups of PLGA at 
the particle surface. 
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6.3   Morphology of Gd-DTPA Encapsulated Nanoparticles 
FESEM pictures were taken to give a direct and close observation of the nanoparticles. 
Compared with SEM, FESEM has higher resolution and can give clearer image of 
samples with small particle size. Fig 6.1 showed the FESEM images of Gd-DTPA 
encapsulated PLGA and MPEG-PLA nanoparticles using double emulsion method or 
nanoprecipitation method. The FESEM confirmed the results of laser light scattering 
(LLS) that MPEG-PLA nanoparticles using nanoprecipitation had small particle size 
around 100nm. For other batches, the particle sizes were between 200~400nm. All 
batches of nanoparticles had spherical shape. However, some particles, such as the PLGA 
nanoparticles using double emulsion showed a sticky state, which might be caused by the 
aggregation of particles. For MPEG-PLA nanoparticles using double emulsion, there 
seemed to be some foggy things around the nanoparticles. This might be the Gd-DTPA 
on or near the surface of the nanoparticles, since most of the hydrophilic PEG chain was 
on the surface of the nanoparticles.  
        
                            (a)                                                                     (b)  
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                        (c)                                                                           (d) 
Fig 6.1 FESEM images of Gd-DTPA encapsulated nanoparticles.(a) PLGA nanoparticles 
using double emulsion, bar=1µm (b) PLGA nanoparticles using nanoprecipitation, 
bar=1µm (c) MPEG-PLA nanoparticles using double emulsion, bar=100nm (d)MPEG-
PLA nanoparticles using nanoprecipitation, bar=1µm  
 
6.4 Drug Entrapment and In Vitro Release Profile of Gd-DTPA 
Encapsulated Nanoparticles 
6.4.1 Drug Entrapment Study 
Table 6.2 Drug entrapment of Gd-DTPA encapsulated nanoparticles with various 
formulations 
Type                                                   Drug Entrapment (%)                    
PLGA(NP*)                                                      <0.5                               
PLGA(DE*)+TPGS                                          1.51 
PLGA(DE*)+PVA                                            0.64 
PLGA +salt(NP*)                                              <0.5 
MPEG-PLA(NP*)                                              0.96                                 
 
MPEG-PLA(DE*)                                              1.32     
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One of the limiting factors to develop nanoparticle based drug carriers is the low 
encapsulation efficiency and drug entrapment. Drug entrapment is an important 
parameter since higher drug entrapment could help to decrease the dose of nanoparticles 
used for further in vivo experiment.  In this experiment, ICP-OES was used to measure 
the content of Gd-DTPA in nanoparticles. Table 6.2 summarizes the drug entrapment of 
Gd-DTPA encapsulated nanoparticles. All of them showed very low entrapment. Due to 
the large amount of Gd-DTPA used during fabrication (45mg Gd-DTPA with 75 mg 
polymer), the encapsulation efficiency for all batches was also very low (<3%). For 
PLGA nanoparticles fabricated by nanoprecipitation, the entrapment was too low (<0.5%) 
and did not have meanings in further application. When drug loaded PLGA nanoparticles 
were fabricated with double emulsion, the drug entrapment increased. Vitamin E TPGS 
emulsified PLGA nanoparticles had the drug entrapment of 1.51%, meaning 100mg 
nanoparticles had 1.51mg drug encapsulated. However, considering the size of the 
particle, which was about 3µm, it is not suitable to develop this kind of particles for 
monitoring their BBB crossing kinetics. For MPEG-PLA nanoparticles, the drug 
entrapment was higher than that of PLGA nanoparticles with comparable or even smaller 
particle size. Thus the following experiments would be based on Gd-DTPA encapsulated 
MPEG-PLA nanoparticles using double emulsion or nanoprecipitation.  
In order to find out the loss of Gd-DTPA in the process of centrifugation, the content of 
Gd-DTPA in the surpernatant was also measured using ICP-OES. For all samples, in the 
first wash, around 80% Gd-DTPA was lost in the supernatant instead of being 
encapsulated into the polymer matrix. This might be caused by the hydrophilicity of Gd-
DTPA, thus hard to be encapsulated or just adhered to the particle surface loosely. In the 
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subsequent washes, the supernatant contained much smaller amount of free Gd-DTPA 
than the first wash, which was less than 3%. Other loss of Gd-DTPA might happen 
during the fabrication process. From these results, we can see that the later two washes of 
nanoparticles can not be skipped in order to guarantee most of the Gd-DTPA was 
encapsulated in the polymer matrix instead of attaching to the surface. 
6.4.2 In Vitro Release Kinetics  
In vitro release of Gd-DTPA from MPEG-PLA nanospheres was investigated in PBS 
solution (pH=7.4) at 37oC in an orbital shaker. This experiment was carried out within 48 
hours. The Gd-DTPA encapsulated MPEG-PLA nanoparticles, which were fabricated by 
either double emulsion or nanoprecipitation, were chosen to take the in vitro release test 
since they had relative higher drug entrapment and favorable particle size.  
Both of the particles showed sustained release with an initial burst as shown in Fig 6.2. 
The initial burst might be caused by the relative easy release of Gd-DTPA near or on the 
particle surface. It is obvious that nanoparticles using double emulsion (DE) had a slower 
release rate than nanoparticles using nanoprecipitation (NP). For DE nanoparticles, less 
than 40% Gd-DTPA was released at the end of 48 hours while this value for NP 
nanoparticle was more than 50%. The reasons might be that MPEG-PLA nanoparticles 
fabricated by nanoprecipitation had much smaller particle size than particles by double 
emulsion. The smaller particles had higher surface area to volume ratio, thus could have a 
higher release rate.   
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Overall, Gd-DTPA encapsulated MPEG-PLA nanoparticles showed favorable release 
profile. However, the release kinetics might be different in in vivo situation since many 
enzymes exist in the body which can cut off the polymer chain and speed the release rate. 























Fig 6.2 In vitro release profile of Gd-DTPA encapsulated MPEG-PLA nanoparticles. 




6.5   MRI Characterization 
Gd-DTPA encapsulated nanoparticles were detected and differentiated by MRI. The MRI 
study was carried out on a 1.5 T scanner with a head coil. Since Gd-DTPA is a kind of 
T1-weighted positive contrast agent, T1 relaxation time was measured and converted to 
the R1 relaxation rate, which equals to 1/T1.  
6.5.1 Calibration Curve of pure Gd-DTPA In Vitro 
T1 relaxation time of pure Gd-DTPA in different concentrations were measured and 
converted to R1 relaxation rate to produce the calibration curve. The Gd concentration 
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was ranging from 0 to 0.2mM. Inversion recovery gradient-echo images were acquired to 
measure T1. The imaging parameters were set as follows: slide thickness=5mm, TR= 25-
6400 ms and TE=12ms. Fig 6.3 shows the calibration curve of Gd-DTPA dissolved in 
water. The six concentrations can be fit into a straight line with high linear correlation 
coefficient of up to 0.9981 and the equation to describe the line was y=4.0077x+0.3148, 
where x is the Gd concentration in millimole/liter and y is the R1 relaxation rate in s-1. 
The slope 4.007 is actually the relaxivity of the contrast agent. 
Although dispersing Gd-DTPA in water is the simplest way to have the MRI test, water 
can not mimic the characteristics of tissues well and nanoparticles can settle down in 
water after a period of time which will make the measurement difficult. Therefore Gd-
DTPA was dispersed in 8% gelatin (w/v) to make another calibration curve and 
compared with the calibration curve which dissolved Gd-DTPA in water. Gelatin can not 
only help to make the nanoparticles evenly distributed in subsequent experiments but also 
can mimic the tissues better. From Fig 6.4, we can see after being dispersed in the gelatin 
gel, the concentration of Gd and R1 relaxation rate still have a linear relationship. The 
linear correlation coefficient was also very high of up to 0.9991. The equation to describe 
the relationship was y=4.9229x+0.716. We can discover the relaxivity of Gd-DTPA in 
gelatin is higher than that in water. 
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R1 relaxation rate in Water





















Fig 6.3 Calibration curve of Gd concentration to R1 relaxation rate in water using pure 
Gd-DTPA 
 
R1 relaxation rate in Gelatin
























6.5.2 Relaxation Rate Characteristics of Gd-DTPA Encapsulated 
Nanoparticles  
The R1 relaxation rate of Gd-DTPA loaded nanoparticles was investigated to study the 
effect of polymer encapsulation. Nanoparticles in both water and gelatin are investigated. 
Gd-DTPA encapsulated nanoparticles were dispersed in the water and gelatin at the 
concentration of 40mg/ml. T1 was measured using the same MRI parameters as 
mentioned above. T1 relaxation time of pure water and blank nanoparticles were also 
measured and converted to R1 relaxation rate. From Fig 6.5, we can discover that pure 
water and blank MPEG-PLA nanoparticles without any drugs had a very low relaxation 
rate compared with Gd-DTPA encapsulated nanoparticles. Therefore the R1 relaxation 
rate of drug loaded nanoparticles is mainly caused by the Gd-DTPA encapsulated. Using 
the calibration curve above, the relaxation rate can be converted to the Gd concentration. 
For nanoparticles fabricated by nanoprecipitation, the converted Gd concentration was 
0.363mM and for nanoparticles by double emulsion, the converted concentration was 
0.684mM. However, considering the drug entrapment which was measured by ICP-OES, 
the Gd concentration for nanoprecipitation and double emulsion nanoparticles should be 
0.70mM and 0.96 mM, respectively. This result showed that after encapsulating into the 
polymer matrix, the R1 relaxation rate of Gd-DTPA decreased. This reduction in R1 
relaxation rate might be caused by the shielding effect of the polymer. Encapsulated Gd-
DTPA was prevented by the surrounding polymer from interacting with the hydrogen 
atoms. 
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Just as mentioned previously, gelatin gel can simulate the tissue characteristics and help 
to prevent the nanoparticles from settling down. 8% gelatin (w/v) was prepared to embed 
the nanoparticles as described by Faranesh et al.(Faranesh et al., 2004) . From Fig 6.6, we 
can see pure gelatin and blank polymeric nanoparticles in gelatin also exerted only small 
relaxation rate, although it was larger than that of water. The R1 relaxation rate of pure 
gelatin was similar to the value reported by Chen et al. (Chen, et al., 2005). In the same 
way, the R1 relaxation rate can be converted to Gd concentration using the calibration 
curve. For nanoprecipitated and double emulsified nanoparticles, the converted 
concentration was 0.267mM and 0.413mM, respectively. It is also smaller than the actual 
concentration of encapsulated Gd-DTPA measured by ICP-OES previously (0.70mM for 
nanoprecipitated MPEG-PLA nanoparticles and 0.96 mM for double emulsified MPEG-
PLA nanoparticles). This also might be caused by the shielding effect of the polymer. Fig 
6.7 shows the MRI images of the Gd-DTPA encapsulated MPEG-PLA nanoparticles and 
the blank nanoparticles both in water and in gelatin. 
From these experiments, we can conclude that positive MRI contrast agent Gd-DTPA can 
still exert their effect after being encapsulated into the biodegradable polymers. However, 
after encapsulating, their R1 relaxation rate decreased due to limited access of water to 

































Fig 6.5 R1 relaxation rate of water, blank MPEG-PLA nanoparticles without Gd-DTPA, 
Gd-DTPA encapsulated nanoparticles using nanoprecipitation and Gd-DTPA 
encapsulated nanoparticles using double emulsion suspended in water  
 



















Fig 6.6 R1 relaxation rate of gelatin, blank MPEG-PLA nanoparticles without Gd-DTPA, 
Gd-DTPA encapsulated nanoparticles using nanoprecipitation and Gd-DTPA 
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Fig 6.7 MRI images of Gd-DTPA encapsulated MPEG-PLA nanoparticles, from left to 
right: 1. blank nanoparticle in water, 2. blank nanoparticles in gelatin, 3. Gd-DTPA 
loaded nanoparticles using nanoprecipitation in water, 4.  Gd-DTPA loaded nanoparticles 
using nanoprecipitation in gelatin, 5. Gd-DTPA loaded nanoparticles using double 
emulsion in water, 6. Gd-DTPA loaded nanoparticles using double emulsion in gelatin. 
TR= 800ms; TE =12ms, 256x256, 0.7mm in-plane and 5mm slice thickness 
 
 
The above experiments investigated the in vitro characteristics of MRI contrast agent Gd-
DTPA encapsulated nanoparticles of biodegradable polymers. The particle size, drug 
entrapment, in vitro releases and MRI effect were tested. These particles have favorable 
characteristics and can be used for further in vivo investigation.  
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Chapter 7 
Conclusions and Recommendations 
7.1 Conclusions 
In this study, we investigated the feasibility of biodegradable PLGA nanoparticles to treat 
brain cancer and cross the blood brain barrier both in vitro and in vivo. Paclitaxel, a 
widely used anti-cancer drug was used as the model drug. The emphasis was put on the 
effect of emulsifiers and surfactants of the nanoparticle formulation. Two natural 
surfactants, DPPC and vitamin E TPGS were used and compared with the traditional 
chemical surfactant PVA. It was found that all batches of nanoparticles had a favorable 
particle size ranging from 245.2nm to 282.8nm. They also had a narrow size distribution 
and negative surface charge. SEM and AFM images revealed that all batches of 
nanoparticles had smooth surface morphology. Moreover, encapsulation efficiency (EE) 
experiment showed that vitamin E TPGS emulsified nanoparticles had a very high EE 
value of 92.30% while the EE values for PVA and DPPC emulsified nanoparticles were 
58.42% and 45.71% respectively. Our in vitro release study demonstrated that PVA 
emulsified nanoparticles showed the fastest release rate of up to 68% while vitamin E 
TPGS emulsified nanoparticles only released about 40% drug during 25 days. Then cell 
viability study was carried out by employing rat glioma cell C6 as the model cancer cell 
line. It was revealed that compared with pure taxol® , paclitaxel loaded nanoparticles had 
comparable effect to kill cancer cells. Our results also showed that both time and 
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concentration had effects on the cell viability to drug loaded nanoparticles and pure 
taxol®.  Longer time and higher concentration would result in less cell viability. 
Fluorescent marker coumarin-6 was incorporated into the PLGA nanoparticles with 
various emulsifiers to carry out the cellular uptake study on MDCK cell line which was 
used as a simple in vitro BBB model. It was found that vitamin E TPGS emulsified 
nanoparticles had the highest cell uptake concentration of 63.8%, which was more than 
two folds of the PVA emulsified nanoparticles. Confocal microscopy was also carried out 
to give direct evidence of the internalization of nanoparticles to the cells. On the other 
hand, commercial fluorescent polystyrene nanoparticles with uniform sizes ranging from 
20nm to 500nm were used to test the size effect on cell uptake. It was found that the 
50nm nanoparticles had the highest uptake percentage by MDCK cell lines. Finally, after 
over coated with tween 80, the fluorescent PLGA nanoparticles were injected into rat 
from tail vein and the brain tissues were cut to slices to observe under fluorescence 
microscope. Fluorescence was observed both in blood vessels and surrounding tissues in 
the brain, which indicated PLGA nanoparticles had the potential to cross BBB in vivo 
with proper emulsifiers and surface coatings. 
MRI contrast agent Gd-DTPA encapsulated biodegradable nanoparticles have also been 
developed for future noninvasive in vivo imaging.  MPEG-PLA was used to fabricate 
nanoparticles using both double emulsion and nanoprecipitation since they exerted 
favorable size of 100~300nm and relative higher drug entrapment. In vitro release was 
also carried out within 48 hours and about 40% gadolinium was released out. MRI 
characterization revealed that both longitudinal and transverse relaxation rate of the Gd-
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DTPA encapsulated nanoparticles were reduced compared with same amount of pure Gd-
DTPA, which might be caused by the reduced access of water to the contrast agent.  
7.2 Recommendations 
In previous study, we used MDCK cell line as a simple BBB model to investigate the 
uptake experiment, furthermore, we should use more accurate model such as the co-
culture system to clarify the mechanism of the particles getting out of the endothelial 
cells of the brain vessels and entering the brain parenchyma. We have also demonstrated 
qualitatively with histological tissue analysis that it is possible for biodegradable PLGA 
nanoparticles with proper emulsifiers and surface coatings to cross the blood brain barrier 
in rat models. In the future, quantitative bio-distribution study of model drug (such as 
paclitaxel) loaded nanoparticles in animals should be tested.  
We have also had preliminary research on MRI contrast agent Gd-DTPA encapsulated 
nanoparticles for potential in vivo imaging. The study so far has been done in vitro. The 
in vivo imaging should be carried out in the future study.  
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